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ABSTRACT 
 
ENHANCING T-CELL RESPONSES TO VACCINATION OF HIV-1 INFECTED 
SUBJECTS ON ANTIRETROVIRAL THERAPY 
Lorenzo Ramirez 
Jean D. Boyer 
With the advancement in anti-retroviral therapy (ART) regimens there has been a 
significant improvement in the quality of life and survival of those individuals infected 
with HIV-1. Even with the benefits to CD4+ cell counts, decrease in viremia and 
inflammatory biomarkers, HIV-1 infected individuals continue to exhibit functional issues 
in their T-cell immune responses to recall antigens and vaccines. Additionally, 
researchers believe that T-cell mediated responses will be important to elicit in a 
therapeutic vaccination setting. These T-cell functionality issues can leave individuals 
infected with HIV-1 at risk from opportunistic infections and co-morbidities. Furthermore, 
a therapeutic HIV-1 vaccine is needed that can elicit responses to help infected subjects 
better control HIV infection so as to potentially reduce the need for long-term therapy. 
However, basic research on HIV is still needed to solidify potential immune correlates 
against HIV and other pathogens affecting HIV-1 infected subjects. Likewise, 
investigation of therapeutic targets that can aid in enhancing T-cell immune responses in 
these individuals is of importance. 
 In this thesis, we examined whether a therapeutic HIV-1 DNA vaccine delivered 
with in vivo electroporation to HIV-1 infected subjects on ART could elicit potent cellular 
immune responses previously suggested to be important in the control of HIV. This 
vaccine strategy demonstrated an enhancement in cell-mediated IFN-! production and 
cytotoxic immune responses to HIV-1. However, until a vaccine or therapy for HIV-1 is 
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developed, these individuals also continue to be at risk for other opportunistic infections, 
such as influenza infection. Supported by previous studies that focus on influenza 
vaccination, we found that a standard dose of the H1N1 vaccine (15µg; Novartis) did not 
elicit sero-protection in all individuals. Importantly, the ability of these individuals to 
respond to vaccination was associated with the frequency of naïve CD4+ T-cells prior to 
vaccination, thereby reinforcing the importance of CD4+ T-cell help and the need for 
better CD4+ T-cell reconstitution. In addition, HIV-1 infected subjects, despite ART, have 
an altered cytokine/chemokine environment. Thereby it is important to explore whether 
targeting the cytokine milieu can lead to improvements in responses to vaccination in 
these individuals. We specifically found that the pro-inflammatory chemokine IP-10 was 
elevated in the sera of those infected with HIV-1 while on ART. Additionally, elevated 
levels of IP-10 were associated with decreased cellular immune responses, which could 
be improved by neutralizing IP-10 prior to antigen stimulation. Therefore, the studies 
herein support the need for better understanding of the basic science of HIV-1 infection 
to uncover and comprehend what potential immune correlates are needed for 
therapeutic treatment of these individuals.!
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CHAPTER 1: 
INTRODUCTION 
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1.1 HIV-1 Infection 
Identified in the early 1980’s, despite the years of extensive research, HIV-1 
infection continues to contribute to significant morbidity and mortality around the world1,2. 
During the acute phase of infection there is increased viral replication, immune 
activation, depletion of CD4+ cells, dissemination of the virus into lymphoid tissues, and 
elevation of inflammatory biomarkers3, 4, 5. The acute phase is followed by a phase of 
chronic infection with continuous immune activation and viral replication, which further 
contributes to the loss of CD4+ T-cells and the eventual progression to AIDS, where 
opportunistic infections place these individuals at risk for complications and death6, 7, 8.  
Several studies examine the role of markers of inflammation and immune 
activation suggesting a predictive role for disease progression. Such studies show 
several prognostic markers during untreated HIV-1 infection that are predictive of rapid 
disease progression. These markers include immune activation9, 10, inflammatory 
cytokines/chemokines, in particular IP-10,4, 11, 12 viral loads, and CD4+ cell counts13. 
Furthermore, chronic HIV-1 infection leads to altered T-cell characteristics, such as an 
accumulation of terminally differentiated T-cells and dysfunction10, 14.  
 
1.2 HIV-1 Infection and Anti-Retroviral Therapy 
  Since the approval of zidovudine (AZT) in 198715, significant enhancements in 
anti-retroviral therapy (ART) have led to an improvement in the quality of life and survival 
of those living with HIV-1 infection16, 17. Even more, improvements to drug regimens have 
led to better adherence and reduction in side-effects that were seen with older regimens; 
these enhancements in turn have helped in reducing transmission18, 19, 20. 
In addition to better survival of these individuals, use of ART also helps lead to 
the rebound of CD4+ cell counts, which are shown to increase for up to seven years in 
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these individuals21, 22, 23. However, these increases in CD4+ cell counts are shown to be 
influenced by pre-ART CD4 counts22, suggesting that the timing of ART initiation can 
influence immune reconstitution. Nonetheless, ART treatment is also shown to lead to 
decreases in viremia to levels below detection within months of starting therapy24, 25. 
Finally, ART also leads to a decline in immune activation and inflammatory markers26, 27. 
Despite these advancements, it is demonstrated that although there is a 
decrease in viremia, a viral reservoir is still present24, 28, 29. This fact may be due to the 
inability of ART drugs to reach all tissues, classified as sanctuaries that could harbor 
viral reservoirs29, 30. Additionally, Hunt et al.31 demonstrate that despite ART, these 
individuals continue to have elevated activated CD4+ and CD8+ T-cells compared to 
healthy HIV-negative individuals. Also, even with ART, these individuals are shown to 
have an imbalanced cytokine and chemokine environment26, 27, 32, 33, 34. 
Observations of residual immune activation and inflammation have led to interest 
in early initiation of ART. A study of long-term ART initiated during early HIV-1 infection 
suggested that there is potential for better immune system preservation and a functional 
cure35. A functional cure is defined as the ability to control infection without the need for 
medication. For example, while not successful in the long-term, very early ART initiation 
in an infant showed the potential for a functional cure36. Therefore, the timing of ART 
initiation could aid in preserving the immune system, and may also help avoid damage 
that may persist in individuals who initiate ART later.  
 
1.3 HIV-1 Infection and Cellular Immune Responses 
Adaptive cell mediated immunity is directed by T-lymphocytes37. Upon infection 
or vaccination naïve CD4+ and CD8+ T-cells become activated and undergo 
differentiation after interacting with a specific antigen that is displayed in the context of 
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self-major histocompatibility (MHC) complex molecules38. CD4+ T-cells differentiate into 
T-helper subsets. Th1 and Th2 subsets dominate most immune reactions, whose 
functions depend on the cytokines they secrete37. Specifically, development of these 
helper subsets is dependent on the type of stimuli present at the initiation of immune 
responses. The presence of the cytokines IL-12 and IFN-! and transcription factors 
STAT-1, STAT-4, and T-bet is shown to induce Th1 subsets important for responses to 
pathogens that infect cells or activate macrophages37. On the other hand the cytokine IL-
4 and transcription factors GATA-3 and STAT-6 are the major inducers of Th2 subsets, 
important in responses against helminthes and allergens37.  CD4+ Th1 cells are also 
involved in activating cells such as macrophages, which aid in the production of 
additional immunological mediators and improves T-cell activation37. As well, CD4+ 
helper T-cells, particularly follicular helper T-cells are involved in promoting humoral 
immunity37. Specifically, upon activation, T-cells migrate to B-cell follicles where they 
help promote B-cell responses, such as clonal expansion, antibody production and 
isotype switching, through cytokines or CD154 dependent mechanisms39. Finally, there 
also exist subsets of CD4+ T-cells involved in regulation of immune responses, these 
cells are know as regulatory T-cells37. 
While naïve CD8+ T-cells with antigen stimulation undergo differentiation into 
cytotoxic T-lymphocytes (CTLs)37. CD8+ T-cells respond by producing cytokines and 
chemokines, such as IL-2, IFN-!, TNF-", and MIP-1"/#, as well as the release of 
cytotoxins, such as perforin and granzyme, from cytolytic granules40. CD8+ cytotoxic T-
lymphocytes can directly kill cells infected with intracellular pathogens37. CD8+ CTLs are 
known to mediate target cell killing, as discussed above through degranulation and the 
production and secretion of cytotoxins such as perforin and granzyme B, which help 
permeabilze cells and activate apoptotic pathways. In addition to cytotoxin-mediated 
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killing, CD8+ CTLs are also able to use contact-dependent mechanisms through their 
expression of Fas ligand, which binds the Fas receptor found on the surface of many cell 
types37.  During acute HIV-1 infection a strong CTL response is shown to contribute to 
the decline in viremia observed41.  
Individuals who are able to control HIV-1 infection in the absence of therapy, 
exhibit strong cellular immune responses that are shown to be important in control. 
Considering this, eliciting these responses in individuals receiving ART, may be 
necessary in targeting HIV-1. Similarly, exploring cellular mechanisms of viral control 
can help researchers understand why those with progressive disease fail to control HIV-
1 infection42. The suggestion that CD8+ T-cells play an important role in controlling HIV-
1 infection come from studies involving CD8+ T-cell depletion and SIV infected rhesus 
macaques, which demonstrate that the presence of a potent CD8+ response is 
associated with lower viral replication and slower disease progression43. In addition, the 
occurrence of viral escape mutations suggests that there is pressure from CD8+ T-
cells44, 45. Additionally, it is proposed that early ART leads to increases in CD4+ helper 
subsets important in maintaining CTLs42, 43, 45. So examining how to enhance the CD4+ 
helper response is of interest as well.  In particular it has been suggested that CD4+ T-
cells, specifically of central memory phenotype, that produce IL-2 are able to help 
maintain proliferative T-cell responses and effector CD8+ T-cell responses46. As well, 
CD4 help may be involved in regulating T-cell differentiation and memory formation, as 
studies during HIV-1 infection suggest changes in T-bet expression in the absence of 
CD4 help47. These findings and others have suggested better HIV control in the 
presence of higher numbers of HIV-specific CD27- CD8+ T-cells48. So if differentiation is 
affected, through abnormal expression of T-bet, this could impact T-cell mediated 
responses against HIV.  
6 
In regards to cellular correlates of protection, Betts et al.40, 49 suggest that poly-
functional T-cells, which include proliferative capacity, secretion of IL-2, IFN-!, TNF-", 
and MIP-1"/#, ability to degranulate and produce cytotoxins, may be important in the 
control of HIV-1 infection50. However, while IFN-! is a measure of an active anti-viral 
immune response, it does not directly inhibit HIV-1 replication or kill cells50, 51. Therefore, 
surrogate markers of killing, such as degranulation and production of perforin and 
granzyme B are theorized to be crucial. Specifically, non-progressors compared to 
progressors are shown to have better proliferative capacity of T-cells, which is 
associated with perforin expression45. Furthermore, use of more direct measures of 
killing, demonstrate that non-progressors are also better at eliminating autologous HIV-
infected CD4+ T-cells in vitro compared to progressors52. Though in regards to HIV-1 
infected subjects receiving ART, Migueles et al.53 indicate that despite ART, these 
individuals, compared to long-term non-progressors, have a lower proliferative and 
cytotoxic capacity53, 54. While this may be due in part to a decay in CD8+ CTLs with long-
term ART50, these findings suggest even more that enhancing these responses in HIV-1 
infected individuals on ART will be necessary to target HIV-1.  
 
1.4 Prophylactic vs. Therapeutic HIV-1 Vaccines 
Many viral vaccines are based on either live-attenuated of whole inactivated 
viruses55. However, for HIV those vaccine strategies have been deemed unsafe due to 
the risk of integration of HIV proviral DNA into the host genome55. Therefore additional 
vaccine modalities such as recombinant and DNA-based vaccines have been of interest. 
Regardless, there has yet to be an effective prophylactic or therapeutic vaccine for HIV. 
The goal of a prophylactic vaccine against HIV would hope for the prevention of HIV 
infection, if possible, or the reduction of viral set points and/or better control once 
7 
infected55, 56. As well, a prophylactic vaccine will need to be effective at all portal of HIV 
entry and must have broad and durable immunity. On the other hand a therapeutic 
vaccine for HIV would aim to treat those individuals who are already infected. Potential 
goals with a therapeutic vaccine are to help enhance the immune responses against 
HIV, reduce secondary transmission, as well as possibly helping in controlling infection, 
aiding in targeting the viral reservoir, and/or eliminate infection (sterilizing cure)57. In 
addition, in ART-treated individuals, it would be a goal for a therapeutic vaccine that 
could potentially help reduce or eliminate the need for prolonged anti-retroviral therapy 
(functional cure).  
The preventative HIV vaccine field has undergone different iterations of vaccines, 
focusing on the induction of neutralizing antibodies, CTL responses, or a combination of 
different immune responses55. With years of different HIV vaccine designs, three major 
trials have elucidated the need to further understand the basic immunology of HIV-1 
infection and possible immune correlates of protection. The STEP and Phambili trials 
aimed at investigating the efficacy of cell-mediated immunity as a prophylactic vaccine58. 
However, both studies were terminated early due to analysis suggesting that vaccination 
was associated with an increase in HIV acquisition55. The researchers concluded that 
the cell-mediated immunity induced by this vaccine did not prevent infection or reduce 
viral set-points. This was suggested to be due to pre-existing immunity to the adenoviral 
5 vector used as well as circumcision status55. A third study, known as the RV-144 trial 
was suggested to show moderate efficacy in individuals who had received the vaccine 
compared to placebo. After analysis of the study it was suggested that antibodies 
against the V1V2 loops55 may be playing a role. Nonetheless, the vaccine did not aid in 
better control of HIV replication or loss of CD4+ T-cell subsets56. The findings in these 
trials suggest that better understanding of the basic science of HIV infection as well as 
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additional investigation of possible correlates of protection are necessary. While studies 
of non-progressors have revealed some potential correlates for HIV-1 control that does 
not mean that those responses would be effective at preventing HIV-1 acquisition.  
In further regards to therapeutic vaccines against chronic infections, like HIV, it is 
important to understand what immune correlates are needed during continuous viral 
replication. This could mean that the antigens targeted prophylactically could differ from 
therapeutic targets57. Likewise, during non-chronic infections there is an important role of 
immune memory, which can help dramatically during a second round of infection57. 
However, it is known that HIV-1 infection can impact normal immune cell differentiation3, 
57. This effect on differentiation could affect the ability of memory cell formation, even 
after the antigen is significantly reduced, as is with ART. Therefore, a therapeutic 
vaccine may need to stimulate effector cells and possibly enhance not only their 
function, but expansion and survival. Even more, understanding the basic science of HIV 
infection, in particular in subjects on ART, could help elucidate potential 
adjuvant/therapeutic strategies to enhance immune responses. Lastly, since CD4+ T-
cells play a role in helping both arms of the immune system, including maintaining CD8+ 
CTLs, exploring how to improve immune reconstitution with ART regimens could help if 
then combined with a therapeutic vaccine that would enhance the anti-HIV response. 
 
1.5 HIV-1 Infection and Non-HIV Infections 
Prior to effective antiretroviral therapy HIV-infected individuals were at 
heightened risk for opportunistic infections due to their immune-compromised status59. 
Specifically, CD4 counts are shown to contribute to the severity and risk for different 
opportunistic infections, however, ART aids in reconstituting these cells22, 60. While 
issues associated with unknown HIV-status, and lack of drug accessibility continue to 
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contribute to morbidity and mortality from opportunistic infections in those infected with 
HIV, some individuals despite ART and CD4+ cell reconstitution are not able to attain 
necessary responses to non-HIV vaccination to protect them completely.  
The Centers for Disease Control and Prevention (CDC)61 establish 
recommended treatment and vaccination guidelines for individuals living with HIV59. The 
CDC details that opportunistic infections can still occur in individuals on ART, but 
maintain that ART should not be interrupted to administer treatment for the opportunistic 
infection. In regards to preventative vaccines, the CDC for 2014 recommends that HIV-
infected individuals with CD4 counts above 200 cells/µl consider receiving vaccines 
against influenza, whooping cough and tetanus (Tdap), pneumococcal disease, hepatitis 
B virus, human papilloma virus, measles, mumps and rubella (MMR if born after 1957, 
but not received the vaccine), chickenpox (if born after 1980 and not received the 
vaccine)61, 62. However, not all vaccines are safe to administer to individuals depending 
on the individual’s immune-compromised severity.  
Current studies suggest that standard influenza vaccines are only moderately 
effective in those infected with HIV and that even with ART, individuals may still be at 
risk of morbidities due to influenza infection63, 64, 65. In order to achieve sero-protection 
individuals infected with HIV often require higher or multiple doses of the influenza 
vaccine66, 67. Similarly, while the conjugate pneumococcal vaccine is shown to protect 
HIV-infected infants, pneumococcal infections remain elevated in those infected with HIV 
despite effective ART68, 69. It is thereby suggested that herd immunity may be most 
beneficial for protecting these individuals. Of particular concern to HIV-1 infected 
subjects is HCV co-infection due to shared routes of acquisition. Studies reveal mixed 
findings regarding the potential benefit of ART on HCV infection. Specifically, Klein et 
al.70 and Kottilil et al.71 show that ART contributes no significant benefit to HCV control. 
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However, effective treatment of HCV in those co-infected with HIV may differ. For 
example in those infected with HIV, treatment with peg-interferon and ribavirin was more 
effective than interferon and ribavirin72. These findings suggest that despite ART, benefit 
to other co-infections may not be present and so these individuals may still be at 
increased risk and may need to receive alternative treatment combinations.  
Finally, in a study by Lange et al.73, they demonstrated that even with the re-
establishment of normal CD4 cell counts, the pre-ART environment is more predictive of 
whether HIV-infected individuals would respond to vaccination against tetanus toxoid, 
diphtheria-toxoid, and keyhole limpet hemocyanin. These findings suggest that despite 
immune reconstitution individuals may still be at risk of disease if they are unable to 
respond adequately to vaccines. Furthermore in HIV-infected children, even with ART 
and increases in CD4 counts and B-cells, antibodies generated to MMR and varicella 
zoster vaccines decline over time, potentially leaving these children at risk despite 
vaccination and can potentially require additional immunizations to maintain protection74. 
Similar findings were found in children who received Tdap75. Even more, while the 
varicella zoster vaccine is safe in HIV-1 infected children, even after two immunizations 
only 60% of children who received the vaccine developed antibodies as compared to the 
HIV-uninfected counterparts76. 
 
1.6 HIV-1 Infection and Co-morbidities 
 Antiretroviral therapy has increased the survival and quality of life of those living 
with HIV-1 infection, but has turned HIV-1 infection into a chronic disease17. It is 
estimated that by 2015, 50% of HIV-infected individuals will be over 50 years of age77. In 
addition, as these individuals live longer, their risk of other co-morbidities, which include 
cardiovascular, renal, pulmonary, neurologic, gastrointestinal, and bone diseases, 
increase78. With the development of better ART regimens the contribution from toxicities 
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due to ART is being minimized79. Therefore the contribution to these co-morbidities from 
ART, HIV-1 infection, and aging needs to be explored. In fact, the elderly, who often 
receive medications other than ART, are at risk for side-effects due to drug-drug 
interactions77. Furthermore, compared to younger HIV-infected individuals, older 
individuals may have less immune reconstitution80 so a balance to deal with HIV-1 
infection and other co-morbidities needs to be investigated especially since these co-
morbities could possibly affect cellular immune responses.  
  
i. T-cell Function 
 With HIV-1 infection thymic involution is seen to occur. This thymic involution is 
also shown to occur with age, which in turn affects these individuals’ generation of naïve 
T-cells81. Without the generation of new cells, the accumulation of terminally 
differentiated cells increases, leaving those infected with HIV and the elderly at risk for 
other infections/co-morbidities, such as influenza virus infection82, 83. Even more, 
Rickabaugh et al.84 demonstrate that despite ART, the changes in naïve CD4+ T-cell 
subsets in those infected with HIV appear to be accelerated compared to age-matched 
healthy controls. Similarly, the damage that occurred during untreated HIV-1 infection 
can contribute to replicative senescence or exhaustion of T-cells due to their chronic 
stimulation14, 85. Therefore, considerations to the initiation of ART are important to 
evaluate, but as is discussed below, ART itself may contribute to issues seen in HIV-1 
infected individuals as they age.  
 
ii. Neurocognitive Disease 
Even with ART, HIV-1 infected individuals’ brain volumetric measures are 
decreased compared to healthy individuals86. Of particular concern in regards to 
individuals on ART, is whether ART drugs are able to enter tissues such as the brain 
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where possible viral sanctuaries may exist14, 87. The presence of neural viral sanctuaries 
could contribute to ongoing damage to the central nervous system. Aside from this, the 
changes seen in metabolic function in those treated with ART can contribute to 
complications in neurocognitive function85. In contrast, older HIV-infected individuals with 
already present neurocognitive impairment may have issues adhering to their ART 
medication, which can have trickledown effects to their immune function, responsiveness 
to vaccination, and response against opportunistic infections88.  
iii. Cardiovascular Disease 
Cardiovascular disease is a leading cause of death in the United States89.  
Several studies have found an increased risk for cardiovascular disease in those 
infected with HIV when compared to age-matched HIV-uninfected individuals89. It is 
proposed, since age impacts immune reconstitution, inability to reconstitute CD4 cell 
counts may contribute to cardiovascular issues90. Yet while ART may be beneficial in 
improving CD4 counts, certain ART drugs, such as protease inhibitors, contribute to 
alterations in lipids, which can exacerbate issues in fat and insulin metabolism and in 
turn promote cardiovascular disease91. However, the benefits associated with ART are 
suggested to outweigh these issues and therefore alternative therapeutic targets are 
being investigated.  
iv. Cancer 
Development of ART has led to a decrease in HIV-associated cancers like 
Kaposi’s sarcoma92. On the other hand, cancers not associated with HIV/AIDS, including 
cancers of the lungs, liver, skin, anus, and others, are on the rise, particularly in men93. 
Reasons behind this increased risk are theorized to be due to the HIV virus itself 
affecting normal cell-cycle regulation, stimulation of potential oncogenes, and 
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enhancement of angiogenesis93. By the same token, those infected with HIV are at risk 
for co-infection with cancer-causing viruses such as HPV, HCV, and EBV93, 94, 95. When 
treating these individuals in the ART era, understanding the risks of chemotherapy while 
on ART is of importance since cancer treatment could contribute to further complications 
and side-effects93. 
v. Other Co-morbidities 
As individuals age, there is an increase in frailty, reduced mobility, and activity. 
These changes are suggested to be accelerated in those infected with HIV and is seen 
to occur despite treatment with ART96. Additionally, toxicities from ART or non-HIV drugs 
are shown to stimulate inflammatory pathways associated with frailty97.  
1.7 HIV-1 Infection and the Cytokine/Chemokine Environment 
 With effective antiretroviral therapy, researchers demonstrate that viremia can fall 
below the limits of detection, and immune activation and inflammation is reduced. 
Regardless of these benefits, even with long-term ART, the levels of immune activation 
remain elevated compared to healthy uninfected individuals31, 98, 99. This chronic immune 
activation can then contribute to further dysregulation of cytokine and chemokine 
production and augment the risk of potential co-morbidities3, 100. Furthermore, a study by 
Almeida et al.101 demonstrated that despite receiving ART for a year, PMBCs from HIV-
infected individuals continue to exhibit abnormal cytokine production. These findings are 
supported by other studies showing that despite ART, abnormal cytokine, such as IL-6, 
and chemokine levels, such as CCL2 and CXCL10, fail to normalize and may contribute 
to disease progression33, 102, 103.  
Since cytokines and chemokines are important in the control of immune 
activation and inflammation, cell function, and mobility, investigating their altered 
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regulation may further reveal relevant therapeutic targets. Such investigation of targets 
like the CCR5 receptor and its ligands has led to the development of anti-HIV 
therapeutic agents104. Conversely, certain cytokines thought to be important in the 
maintenance of T-cells and which are normally anti-viral in function are shown to actually 
further contribute to viral replication. For example, IL-7, a cytokine important in 
thymocyte proliferation and survival, is shown to lead to an increase in HIV viral 
replication, and in those individuals on ART, IL-7 is demonstrated to reactivate latent 
proviral DNA105, 106.  
Understanding what contributes to the observed chronic activation is of interest in 
order to better target these issues and so as to improve immune function in these HIV-
infected individuals. Studies suggest several potential sources for the chronic activation 
including residual low-level replication, microbial translocation, co-infection with other 
pathogens such as HCV, depletion of immuno-regulatory cell subsets, as well as defects 
that are a byproduct of HIV-infection prior to ART initiation99, 107, 108. Further, 
understanding the effect that the dysregulated cytokine and chemokine environment 
plays in affecting immune function and reconstitution can have implications for correcting 
these issues. For instance, HIV-1 infected subjects with high levels of the pro-
inflammatory chemokine IP-10 are more likely to have immunological treatment failure 
following HAART109. As mentioned above investigation of CCR5 and its chemokine 
ligands has led to development of therapeutics that have aided in understanding how to 
better inhibit HIV replication110. Now with ART, HIV-1 replication is decreased 
significantly, however investigating other possible associations HIV-1 infection post-ART 
has with the chemokine system can reveal additional targets to improve immune function 
in these individuals. 
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i. IP-10/CXCL10  
 Interferon-!-inducible protein-10kDa (IP-10), also referred to as CXCL10 or 
small-inducible cytokine B10, is a 10kDa chemokine part of the CXC family of 
chemokines9. IP-10 is produced by a wide-range of cell types that include monocytes, 
innate immune cells such as neutrophils and eosinophils, lymphocytes, epithelia cells, 
endothelial cells, stromal cells, hepatocytes, astrocytes, and keratinocytes111, 112. The IP-
10 protein can be induced by a host of factors, which in addition to IFN-!, can be 
induced by Type-I interferons IFN-"/#, weakly by TNF-" (unless it synergizes with IFNs), 
IL-12, stimulation of toll-like receptors, RIG-I like receptors, and RNA helicases112, 113, 114, 
115, 116. Expression of the IP-10 protein requires binding of a STAT1-STAT2 heterodimer 
to the IP-10 promoter117. The promoter itself for IP-10/CXCL10 contains a functional 
IRSE and NF-$B1 element 118. 
Along with MIG/CXCL9 and I-TAC/CXCL11, IP-10 binds the CXCR3 receptor, a 
seven trans-membrane G-protein coupled receptor, with intermediate affinity compared 
to MIG and I-TAC9, 119. The CXCR3 receptor can be expressed on NK cells, NKT cells, 
plasmacytoid dendritic cells, certain B-cell subsets, macrophages, and activated T-
lymphocytes9, 120. Expression of CXCR3 on immune cells is then shown to allow entry of 
these cells into sites of inflammation and restricted sites, such as the brain121, 122. In 
humans, the CXCR3 receptor is coupled to a G"i protein and has 3 isoforms, CXCR3-A, 
CXCR3-B, and CXCR3-Alt. The CXCR-B isoform can also bind CXCL4 and acts 
inhibitory in nature compared to the CXCR3-A isoform123.  
For binding of IP-10, MIG, and I-TAC to the CXCR3 receptor, the sulfated N-
terminus of the receptor is necessary. For IP-10 the proximal16 amino acid residues of 
the N-terminus of the receptor are also required120. In regards to internalization of the 
CXCR3 receptor, this also requires the carboxyl terminal and beta-arrestin-1 domains124. 
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Along with IP-10’s binding to these regions for receptor internalization, binding also 
initiates signaling pathways involved in chemotaxis and calcium mobilization124, 125. 
Moreover, internalization of the receptor and calcium mobilization initiate signaling 
cascades involving Akt and kinases such as p38126. Additionally, IP-10 is shown to play 
a role in regulating apoptosis, angiostasis, cell growth, and proliferation9. Furthermore, 
the IP-10/CXCR3 signaling pathway is shown to exert signals that may disrupt the 
immunological synapse, thereby potentially affecting normal TCR signaling127.  
The IP-10 protein can exist both in its “long” agonist form and as a shorter 
competitive antagonist form128. In addition, the antagonist form can still bind the CXCR3 
receptor, but blocks signaling129. The antagonist form results from a two amino acid N-
terminal truncation due to processing by the amino-peptidase CD26 (dipeptidyl 
peptidase IV, DPPIV)130. CD26 is a 110kDa protein expressed on the surface of mature 
thymocytes, activated T and B-cells, NK cells, macrophages, endothelial, and various 
tissue epithelial cells131, 132. CD26’s expression on cells increases 5-10 fold following 
activation of cells and can also exist in an active soluble form. CD26 exerts its function 
through its extracellular domain, which can cleave dipeptides from the N-terminus of 
proteins, such as IL-8 and IP-10, and in turn leads to different isoform production or 
protein degradation130, 131.   
 
ii. IP-10 and HIV-1 Infection 
IP-10 is found to be elevated not only during untreated HIV-1 infection, but 
despite ART, remains elevated compared to healthy HIV-uninfected controls133, 134, 135. 
CXCL10 is also shown to stimulate HIV viral replication and blocking IP-10’s interaction 
with CXCR3 reduces this replication136. Furthermore, with this elevation, IP-10 is shown 
to be predictive of not only viral loads in HIV-1 infected individuals, but also predictive of 
rapid disease progression12, 134. On a similar note, HIV controllers with elevated IP-10 
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levels are shown to have higher immune activation and lower CD4+ cell counts137. 
Conversely, Lajoie et al.138 demonstrated that HIV-exposed sero-negative sex-workers 
have significantly lower levels of IP-10 in their mucosa compared to their HIV-negative 
and HIV-positive counterparts. These findings suggest a protective role of low IP-10 
levels. In addition to canonical induction of IP-10, HIV-1 infection can induce high levels 
of IP-10 through stimulation of TLR7/9 dependent pathways114. IP-10 has also been 
found to be elevated in the cerebrospinal fluid of HIV-1 infected subjects exhibiting viral 
replication in the CNS139. Furthermore, HIV-1 proteins are shown to take advantage of 
the pleiotropic effects of IP-10 and exacerbate disease. Specifically, HIV’s Tat helps 
induce IP-10 by antigen-presenting cells thereby recruiting more targets140, 141. While 
gp120 and Nef are shown to induce IP-10 in astrocytes contributing to toxicity and in turn 
neuronal cell death142, 143. Besides its effects during untreated HIV-1 infection, IP-10 is 
also associated with immunological treatment failure during HAART109.  
  
iii. IP-10 and HCV Infection 
 The CDC reports that 25% of individuals living with HIV are co-infected with 
hepatitis c virus and in those HIV-infected individuals who are injection drug users, 80% 
are co-infected with HCV144. Furthermore, co-infection with HIV is shown to accelerate 
HCV disease progression145. Thereby understanding HCV infection can help inform HIV-
1 infection. As mentioned above, IP-10 is elevated in HIV-1 infection and when 
examining subjects mono-infected with HCV, the levels of IP-10 are not only elevated, 
but also correlate with markers of liver damage and inflammation. Moreover, the levels 
of IP-10 during co-infection when compared to mono-infected individuals are shown to 
be even more elevated145. These findings suggest that exploring IP-10 in these patient 
populations can have potential benefits for both HIV and HCV infection.  
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 Increased levels of IP-10 in HCV infection are also associated with increased 
HCV viral loads, fibrosis of the liver, and are predictive of responsiveness to therapy146. 
The effect of IP-10 on responsiveness to HCV therapy has exhibited similar results in 
subjects co-infected with HIV147. Finding it contradictory that a chemokine involved in the 
recruitment of immune cells to sites of infection serves as a negative prognostic marker 
led to a more in depth investigation of IP-10 during HCV infection. Casrouge et al.130 
demonstrated that IP-10’s antagonist form through potential processing by CD26 is 
elevated in HCV infected individuals, suggesting that IP-10 antagonism may be present 
when IP-10 is elevated in these individuals. Another study by Soderholm et al.148 indicate 
that individuals with lower concentrations of soluble CD26 (sCD26) have better 
treatment outcomes compared to individuals with elevated sCD26. Additionally, lower 
sCD26 levels are associated with higher HCV-specific CD8+ T-cells in the blood148. 
These findings would suggest that lower sCD26 could be associated with less IP-10 
antagonism and better T-cell functionality.  
 
 iv. IP-10 and Other Diseases 
 Similarly in subjects with hepatitis B virus infection, Hou et al.149 have shown that 
IP-10 correlates not only with HBV viral loads, but also with increased levels of the 
exhaustion marker PD-1 on T-cells, suggesting a potential impact of elevated IP-10 
levels on functionality of T-cells.  Additionally, in individuals with HIV-1 infection, 
elevated levels of IP-10 can potentially affect the ability of these subjects to clear H1N1 
virus infections150.  
 Aside from viral infections, IP-10 is also elevated in a number of other diseases. 
Specifically, IP-10 is suggested to play a role in the immuno-pathogenesis of rheumatoid 
arthritis151. Likewise, a study by Yellin et al.152 further demonstrated the impact of IP-10 
in rheumatoid arthritis, showing that blocking of IP-10 led to clinical efficacy in patients 
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that were part of a phase-II clinical trial.  Again, IP-10 is elevated in both Type-1 and -2 
diabetes153, 154, 155, chronic spinal cord inflammation156, and airway diseases, such as 
asthma157. Findings on elevated levels of IP-10 have targeted it as a potential biomarker 
for not only HCV infection158, but also tuberculosis159.  
 Additionally, while IP-10 is beneficial in certain cancers, such as breast 
cancer152160, this may not always be the case. Rainczuk et al.161 found evidence of the 
antagonistic form of IP-10 in serous epithelial tumors, which correlated with less T-
lymphocyte infiltration and potentially negative prognosis for patients having higher 
levels of the IP-10 antagonistic form.  
 
1.8 Introduction to Aims of Thesis 
 Years of extensive research in the hopes of identifying and developing an 
effective vaccine against HIV that could lead to a functional cure and/or better targeting 
of the viral reservoir has yet to be accomplished. With amazing progress in the field of 
antiretroviral therapies, HIV-1 has gone from being a death sentence to a manageable 
chronic disease that allows individuals to live a better and longer life. Aside from 
potential side-effects of long-term ART use, the HIV-1 infected population continues to 
age and it has become apparent that damage caused by the HIV virus has left 
individuals with compromised immune systems, particularly the preferential depletion of 
CD4+ helper subsets. Therefore, this thesis investigates hypotheses aimed at 
understanding 1) whether a therapeutic DNA-based vaccine strategy can elicit potent 
cell-mediated immune responses suggested to be important in HIV-1 control; 2) the role 
that pre-vaccination cell-mediated factors may play in vaccine responses to non-HIV 
infections, specifically influenza; And 3) the impact that the imbalanced 
cytokine/chemokine milieu may have on T-cell responses in HIV-1 infected individuals 
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on stable therapy. These hypotheses can lend support for research involved in better 
understanding the timing of ART initiation and preservation of important cell-subsets and 
its effect on cell-mediated responses to vaccines. As well, the research contained herein 
can elucidate what responses may still need to be improved further as well as identify 
possible therapeutic targets to enhance cell-mediated immunity.  
 
i. Improving cell-mediated immune correlates of protection against HIV-1 
 Studies by Betts et al.40, 49 and Migueles et al.162 have expanded our 
understanding of potential cell-mediated immune correlates of protection against HIV-1 
infection.  These studies have examined how long-term non-progressors and controllers 
who in the absence of antiretroviral therapy are able to control HIV-1 infection and 
increase their time to disease progression.  
 Specifically, these studies demonstrate the significance of multi-functional T-cell 
responses, proliferative capacity, and ability of CD8+ CTLs to kill virally infected cells. 
Thereby in the development of a therapeutic vaccine against HIV-1, eliciting these 
responses will be a significant task. Therefore, the first study examined in this thesis 
explores the use of a DNA based vaccine, not only as a safe strategy to administer to 
HIV-1 infected individuals, but also a good method to elicit cell-mediated immune 
responses against HIV-1 antigens. An additional aim is to examine potential factors that 
may dampen vaccine responses against HIV-1.  
 
ii. Understanding non-responsiveness to vaccines against potential opportunistic 
infection. As has been discussed by various researchers, HIV-1 infected individuals 
despite effective antiretroviral therapy continue to show issues in T-cell regeneration and 
function3, 14. Additionally, findings as to the benefit of ART for the protection from 
opportunistic infections are varied. This means that HIV-1 infected individuals may still 
21 
be at risk for complications from opportunistic infections, one such being influenza 
infection. The need to vaccinate the population against influenza viruses yearly and the 
risk of the rise of new pandemic strains leaves immuno-compromised individuals in 
jeopardy. Therefore, in order to better understand why certain individuals respond 
properly to non-HIV vaccines while others do not, we sought to examine responses to 
H1N1 vaccination. We hypothesized that chronic immune activation that persists in 
individuals on ART may play a role in responses to H1N1 vaccination and in turn the 
ability to achieve sero-protection. 
 
iii. Exploring residual issues affecting immunogenicity in the presence of stable 
antiretroviral therapy.  With stable ART, it is demonstrated that viremia declines, 
inflammation and immune activation also decline, and there is immune reconstitution of 
certain cell subsets, specifically CD4+ cells10, 21, 25. Therefore, in the absence of high 
levels of HIV viral replication and immune activation the question arises as to why there 
remain problems in T-cell functionality. In addition to potential complications that may 
come about from possible low-level HIV viral replication, other co-pathogens, and 
microbial translocation, the mediators of some of these issues, the cytokines and 
chemokines, may be potential therapeutic targets that can aid in boosting 
immunogenicity and sero-protection against vaccines. Therefore, we hypothesize that 
exploring the altered cytokine/chemokine environment that is present in HIV-1 infected 
individuals can offer us ways in which to boost cell-mediated immune responses. 
 
iv. Investigating IP-10 as a potential therapeutic target in improving vaccine 
immunogenicity. IP-10/CXCL10 is up-regulated in several diseases and is a negative 
prognostic marker for many of them including HCV130 and HIV-1 infection12. Interestingly, 
IP-10 remains elevated in HIV-1 infected individuals on stable ART. So using research 
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from the HCV field regarding the role of IP-10 in responsiveness to therapy can help 
inform the field of HIV in better understanding IP-10’s role in chronic HIV infection. 
Furthermore, the ovarian cancer field has further expanded a potential role that IP-10’s 
antagonistic form may play in successfully treating patients161. Hence, in the third study 
of this thesis we hypothesize that elevated levels of IP-10 present in HIV-1 infected 
individuals on ART can impact T-cell function and in turn responsiveness to vaccination. 
Additionally, targeting of IP-10 and/or its receptor, CXCR3 could aid in improving cellular 
immune responses.    
 
v. Overarching aims of this thesis. The aims of this thesis contained herein focus on 
improving T-cell mediated immune responses shown to be important in the control of 
HIV-1 infection during acute infection and in long-term non-progressors. Additionally, this 
thesis aims to understand what factors play a role in non-responsiveness to vaccination 
and what factors present after the initiation of ART contribute to non-responsiveness. 
Finally, examining the impact from the dysregulated cytokine/chemokine milieu, 
specifically elevated IP-10 levels, on T-cell function, can aid our understanding in 
improving vaccine strategies both for therapeutic HIV-1 vaccination and non-HIV 
vaccination, specifically influenza. 
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CHAPTER 2: 
Therapeutic Immunization of Synthetic Consensus HIV env, gag, and 
pol DNA in HIV Infected Individuals Induces Potent Cellular Immune 
Responses and Synthesis of Granzyme B, Perforin. 
 
 
“Even if HIV prevention efforts were optimally implemented to achieve a new infection 
rate of near zero, recidivism could threaten this success.” 
 –Dr. Anthony Fauci (N. Engl. J. Med. 2014; NIAID) 
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2.1 Abstract 
In this phase-I clinical trial we examined the safety and immunogenicity of 
immunization of HIV-1 infected individuals on stable antiretroviral therapy with 
therapeutic vaccination. Twelve HIV-1 infected subjects on stable ART received four 
doses of the PENNVAX®-B vaccine (encoding synthetic consensus HIV env, gag, and 
pol) delivered with in vivo electroporation. The vaccine was safe and well tolerated. 
Investigating the immunogenicity elicited by the vaccine demonstrated the production of 
IFN-! by both CD4+ and CD8+ T-cells. Additionally, immunization with this vaccine also 
induced CD8+ T-cells to degranulate and produce perforin and granzyme B in response 
to stimulation with HIV antigens. This study demonstrates the capability of a therapeutic 
DNA vaccine against HIV-1 to induce potent responses suggested to be important in the 
control of HIV-1 infection.  
 
The study in this chapter was conducted in collaboration with others, including Drs. 
Morrow, Tebas, and Weiner. Our lab performed ELISpot and flow cytometric 
immunological assessments. 
 
Citation: Morrow, MP, Tebas, P, Yan, J, Ramirez, LA, Slager, A, Kraynyak, K, Diehl, M, 
Shah, D, Khan, A, Lee, J, Boyer, J, Kim, JJ, Sardesai, NY, Weiner, DB, Bagarazzi, ML.!
Synthetic Consensus HIV-1 DNA induces potent cellular immune responses and 
synthesis of granzyme B, perforin in HIV infected individuals. In Review.  
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2.2 Introduction 
 i. Development of a Therapeutic Vaccine Against HIV-1 
 With several years of arduous research, the question remains as to whether a 
cure against HIV is possible. Over twenty years of research has led to significant 
enhancements in antiretroviral drug regimens, which can succeed at inhibiting HIV-1 
replication. Similarly, providing condoms, male circumcision, pre-exposure prophylaxis 
drugs in addition to ART has reduced the risk of HIV transmission and acquisition163. 
However, these drugs and resources have and continue to have obstacles, including 
issues with adherence, accessibility, and side-effects/toxicities164.  Furthermore, while 
this has indeed improved the lifestyle and survival of people living with HIV17, the long-
term need to have these individuals on drugs for the rest of their lives is not only costly 
to those being treated, but also to the institutions that need to keep developing, 
improving, and delivering these drugs. Therefore, the need to generate a functional cure, 
or a therapeutic treatment that could reduce the need for long-term therapy is 
necessary164. Additionally, as Katlama et al.165 explain, the development of a therapeutic 
vaccine that could assist in boosting immune responses against HIV can help better 
target the viral reservoir. Specifically, if a therapeutic vaccine can boost cell mediated 
immune responses, combine that vaccine with an agent that elicits the virus from the 
latent reservoirs, together this strategy could help eliminate and target the virus164, 166.  
 However, the HIV vaccine field has gone back in forth in regards to T-cell based 
vaccines and those that attempt to elicit broadly neutralizing antibodies. Nonetheless, 
the field of HIV vaccines has seen both setbacks as with Merck’s STEP trial167 and slight 
successes as with the RV144 trial; it is still suggested that in order to better treat HIV 
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infection both arms of the immune system will likely play significant roles168.  
Nonetheless it is possible that responses necessary in a prophylactic setting may not be 
effective in a therapeutic setting. In regards to T-cell vaccines, Hansen et al.169 
demonstrated that a T-cell based vaccine against SIV, while not protective from HIV 
acquisition, could elicit SIV-specific CD8+ T-cell responses which are associated with 
the control of infection. In addition, research on therapeutic vaccines has shown that 
several vaccine modalities including viral vector-based (e.g. Modified vaccinia Ankara 
vector-based), dendritic cell-based (e.g. DCV2/MANON07-ORVACS), subunit-based 
(e.g. Vacc-4x), and DNA-based (e.g. DermaVir) vaccines can elicit immunogenic T-cell 
responses264.  Therefore, a therapeutic HIV vaccine that could help infected individuals 
control infection, possibly with reduced need for ART, or help target latently infected 
cells through the boosting of T-cell mediated responses is of investigation in this study. 
 Moreover, understanding of potential cell-mediated immune correlates of 
protection have come from examining those individuals who are able to maintain control 
of HIV in the absence of therapy and have limited their disease progression. Studies, by 
Migueles et al.52, 53, Hersperger54 and Betts et al.49 have demonstrated the role of not 
only a poly-functional T-cell response, but also the importance of CTL cytotoxic capacity 
and killing of infected cells in the control of HIV-1 infection. Recenlty, Ndhlovu et al.166170 
also demonstrated that HIV controllers maintain a broad HIV-specific CD8+ T-cell 
memory response against HIV gag, which may play a role in long-term viremic control. 
Additionally, while broadly neutralizing antibodies may be important to elicit as well, B 
cells also need assistance from functional T-cells in order to help initiate and maintain B 
cell responses.  
As mentioned above, a variety of vaccine modalities have been investigate for 
the use as therapeutic vaccines, these strategies include DNA based vaccines, dendritic 
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cell-based vaccines, and nonreplicative viral vectors, such as canarypox-based 
vaccines264. The study in this chapter implemented the use of a DNA vaccine combined 
electroporation for enhanced transfection of cells. Compared to other vaccine modalities, 
such as live vaccines or recombinant viral vectors, DNA vaccines, which use plasmid 
constructs, offer a safer strategy to target HIV-1171. With improved design and delivery of 
DNA vaccines, their immunogenicity has and continues to improve in generating both 
humoral and cell-mediated immune responses171. Furthermore, the DNA PENNVAX®-B 
vaccine delivered with electroporation was previously shown to be safe and elicit CD4+ 
and CD8+ T-cell responses in HIV sero-negative individuals (HVTN protocol 080 
NCT00991354). Thus, in this study we investigate and characterize T-cell responses, 
including IFN-! production and cytotoxic capacity, in response to vaccination with a 
therapeutic DNA vaccine against HIV env, pol, and gag antigens.  
 
2.3 Results 
 i. Study design 
 The study described in this chapter was an open label, phase I clinical trial 
conducted at one center in the United States (NCT01082692). The study protocol was 
approved by an Institutional Review Board and adhered to the guidelines of Good 
Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained 
prior to study enrollment. For inclusion into the study, adult HIV-1 infected male and 
female subjects had to be between 18 and 55 years of age, currently receiving a highly 
active antiretroviral therapy (HAART), needed to have undetectable plasma viral loads 
(<75 copies/ml), CD4+ lymphocyte counts %400 cells/µl, and nadir CD4+ lymphocyte 
counts >200 cells/µl. Counts were documented twice on different occasions within 60 
days of enrollment into the study. Female subjects could not be pregnant or nursing, and 
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needed a negative serum pregnancy test within 30 days of entry into the study, and 
finally must have a negative urine pregnancy test on the day of the first therapeutic 
vaccine dose. Individuals were excluded if they had any past or present AIDS-defining 
illness, malignancy needing chemotherapy, autoimmune disease, or had received any 
other immunomodulatory therapy within 4 weeks of study entry. A timeline depicting 
screening for eligibility up to and including analysis can be seen in figure 2.1. 
The aims of this study were to examine the safety and immunogenicity of a 
therapeutic HIV-1 DNA vaccine delivered with electroporation in HIV-1 infected 
individuals on stable antiretroviral therapy. The PENNVAX®-B vaccine is a cocktail of 3 
expression plasmids that contain the genes that encode synthetic HIV-1 Clade B env, 
gag, and pol. Subjects (n=12) received four doses of the PENNVAX®-B vaccine 
delivered intramuscularly followed immediately by electroporation with the 
CELLECTRA® 2000 Adaptive Constant current device. Each dose contained 3mg of the 
expression plasmids in equal proportions. Doses were administered as shown in figure 
2.2. Blood was also collected at the time-points depicted in figure 2.2 as well as safety 
assessments on time-points where the vaccine was administered. Demographics and 
characteristics of the study population are depicted in Table 2.1. The average age of the 
subjects was 42.6 years and ranged between 31-55 years. Eleven of the twelve subjects 
were male, and 58% identified as black and 92% as non-Hispanic or Latino.  
All in all immunization with the PENNVAX®-B vaccine delivered with 
electroporation was well-tolerated and no severe, life-threatening, or adverse events 
occurred during the course of this study.  
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Figure 2.1. Schematic of eligibility, determination, enrollment, study conduct, 
and analysis.!
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Figure 2.2. Study schedule and immunization time-line for participants of the 
study. The schematic depicts time-points of immunization, pain assessment 
(P.A.), and collection of blood for immunologic and virologic assays. !
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Table 2.1. Demographic and immunologic characteristics of study participants. 
Characteristic   Subjects (n=12) 
Age, y     
   Mean  42.6 
   Range  31-55 
Sex, n (%)     
   Male  11 (92) 
   Female  1 (8) 
Race, n (%)     
   White  5 (42) 
   Black or African American  7 (58) 
Ethnicity, n (%)     
   Hispanic or Latino  1 (8) 
   Non-Hispanic or Latino  11 (92) 
Body Mass Index, kg/m2     
   Mean  27.7 
   Range  21-40.4 
CD4+ T-cell count at screening, cells/µl     
   Mean  733 
   Range   461-993 
Nadir CD4+ T-cell count*, cells/µl     
   Mean  505 
   Range  203-877 
HIV-1 viral load at screening, copies/ml     
   Modes  20, 48 
   Range   20-63 
*n=11, data not available for one subject  
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ii. IFN-! Induction in PBMCs by Vaccination with PENNVAX®-B 
IFN-! is an important measure of innate and adaptive anti-viral responses261. 
Using a standard IFN-! ELISpot assay we measured cellular immune responses elicited 
by immunization with PENNVAX®-B. We specifically examined IFN-! production in 
response to the antigens included in the vaccine, that is env, gag, and pol, across the 
immunization time-line. Each of the individual 12 subjects’ IFN-! responses to env, gag, 
and pol at each time-point can be seen in figure 2.3. Time-points for each subject’s 
peak responses are as follows: Subject 03-001 (gag: wk 18; pol: wk 8; env: wk 8), 
subject 03-002 (gag: wk 48; pol: wk 18; env: wk 48), subject 03-005 (gag: wk 10; pol: wk 
10; env: wk 10), subject 03-006 (gag: wk 24; pol: wk 8; env: wk 24), subject 03-007 (gag: 
wk 24; pol: wk 48; env: wk 24), subject 03-008 (gag: wk 4; pol: wk 24; env: wk 4), subject 
03-010 (gag: wk 16; pol: wk 16; env: wk 18), subject 03-011 (gag: wk 48; pol: wk 48; 
env: wk 48), subject 03-013 (gag: wk 48; pol: wk 48; env: wk 48), subject 03-015 (gag: 
wk 48; pol: wk 48; env: wk 48), subject 03-016 (gag: wk 10; pol: wk 10; env: wk 18), 
subject 03-017 (gag: wk 16; pol: wk 16; env: wk 16). 
 When examining day 0, peak, and memory (week 48) vaccine responses, we 
found IFN-! responses peak at 692.6±436.4, 614±344.5, and 341.0±243.8 SFC/106 
PBMCs for gag, pol, and env respectively. Comparing day 0 responses to peak 
responses demonstrated a significant increase in response to vaccination (Day 0-gag: 
364.2±310.2 SFC/106 PBMCs, p=0.0010; Day 0-pol: 372.0±384.0 SFC/106 PBMCs, 
p=0.0068; Day 0-env: 175.1±155.1 SFC/106 PBMCs, p=0.0010; figure 2.4). When 
looking at the subjects individually, we also see that vaccination led to IFN-! responses 
great than 1000 SFC in some of the subjects (figure 2.3) Additionally, while there was 
an increase in IFN-! production during memory responses (Week 48), these responses 
were not significantly elevated compared to Day 0 (gag: 364.2±310.2 vs. 412.0±398.8 
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SFC/106 PBMCs; pol: 372.0±384.0 vs. 454.5±454.2 SFC/106 PBMCs; env: 175.1±155.1 
vs. 199.4±195.9 SFC/106 PBMCs; figure 2.4). In addition, two subjects did not have 
enough sample available to examine memory responses (Week 48). Furthermore, to 
determine if there was an increase in ELISpot responses to non-vaccine antigens, we 
examined subjects’ IFN-! ELISpot response to HIV Nef antigen, which was not part of 
the vaccine. However, vaccination did not lead to a significant increase in IFN-! 
response to Nef (p=0.6569; figure 2.5). 
We next sought to determine which individuals exhibited responses that would 
classify them as responders to vaccination. Since subjects’ responses prior to the first 
vaccine dose were examined multiple times, a pre-vaccine ELISpot response for each 
antigen (gag, pol, env) was determined for each subject. Using this pre-vaccine 
response we required subjects’ IFN-! ELISpot responses to be at least 2 standard 
deviations above the pre-vaccine response in order to be classified as a responder to 
the particular HIV antigen (gag, pol, or env). Following these criteria, all of the twelve 
subjects were shown to be responders to at least one of the vaccine antigens, with the 
majority of the subjects (11/12) being responders to pol. Nonetheless, 8/12 subjects 
were positive responders to gag and half showed a response to env (Table 2.2). Each 
individual’s response to each antigen is depicted in Table 2.3. Moreover, nine of the 
twelve subjects showed positive responses to more than 1 of the antigens, and 4 
subjects exhibited a response to all three. Additionally, eight of the twelve subjects 
demonstrated positive responses at more than one time-point during the immunization 
time-line.   
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Figure 2.3. IFN-! ELISpot responses to gag, pol, and env across the study time-line for 
each individual study participant. Note that subject 03-010 did not have sample available 
for week 24 and 48; and subject 03-008 did not have sample available for week 48. 
Graphs depict IFN-! SFC/106 PBMCs. Blue color indicated response to gag; red color 
represents response to pol; and green color represents response to env. 
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Figure 2.4. IFN-! ELISpot responses to individual gag, pol, and env HIV-1 antigens 
part of the PENNVAX-B® vaccine on day 0, the peak of response, and memory (8 
months after the final dose of PENNVAX-B®). Day 0 responses were significantly 
lower than peak responses (gag: p=0.001; pol: p=0.0068; env: p=0.001). Graph 
depicts IFN-! SFC/106 PBMCs. 
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Figure 2.5. IFN-! ELISpot responses to HIV-1’s Nef antigen (not part of PENNVAX-B®). 
This served as a control for natural variation in responses to HIV antigens. ELISpot 
responses to Nef did not differ significantly between baseline and peak response for the 
individuals in this study. Graph depicts IFN-! SFC/106 PBMCs. 
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Table 2.2. IFN-! ELISpot response to PENNVAX-B® HIV-1 antigens. Responders to 
gag, pol, and env by subject. 
Patient ID Gag Pol  Env 
03-001 - + - 
03-002 + + + 
03-005 - + - 
03-006 + - + 
03-007 + + - 
03-008 - + - 
03-010 - + + 
03-011 + + + 
03-013 + + - 
03-015 + + + 
03-016 + + - 
03-017 + + + 
 
 
 
Table 2.3. IFN-! ELISpot, PENNVAX-B® response summary. 
# of Responders to at least 1 antigen 12/12 
# of Responders to Gag 8/12 
# of Responders to Pol 11/12 
# of Responders to Env 6/12 
# of Responders to more than 1 antigen 9/12 
# of Responders to all 3 antigens 4/12 
# of responders at more than 1 time-point 8/12 
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iii. Cytotoxic capacity of CD8+ T-cells 
 We next wanted to determine if vaccination with PENNVAX®-B induced CD8+ T-
cell responses associated with CTL functions. Specifically, while IFN-! production is 
suggestive of an anti-viral response5, functions associated with the identifying and killing 
of infected target cells are suggested, by studies of HIV controllers, to be important for 
control of HIV-1 infection53. We therefore examined the ability of CD8+ T-cells to 
degranulate, through expression of CD107a, and produce perforin and granzyme B. 
However, one subject  (03-010) did not have enough sample to analyze this response. 
We used the gating strategy depicted in figure 2.6 to identify CD8+ T-cells that could 
degranulate and produce the cytotoxins perforin and granzyme B. Furthermore, the 
lower cut off of the assay is 0.05%. Hence, we examined the impact of vaccination with 
PENNVAX®-B compared to baseline CD8+/CD107a+/Perforin+/Granzyme B 
frequencies.  
 We found that 7 of the 11 subjects examined demonstrated CD8+ cytotoxic 
responses that were above the lower cut off of the assay. In addition, 6 of those 7 
subjects demonstrated responses that exceeded baseline frequencies and of which 
were as high as 0.49% (figure 2.7).  While on the other hand 4 of the 11 subjects 
examined showed weak CD8+ CTL responses or responses that did not exceed 
baseline frequencies, with one subject not showing a response at all. This demonstrated 
that PENNVAX®-B can potentially enhance CD8+ CTL responses associated with 
control of HIV-1 infection, however, not all subjects exhibited a boost in response. 
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Figure 2.6. Multi-parameter flow cytometry panel used for gating the CD8+ CD107a+ 
Perforin+ Granzyme B+ population. We gate the live population followed by our CD3+ 
population, then for our CD8+ T-cell subset. On this subset we gate for both our 
CD107a+ and Perforin+ Granzyme B+ populations. We then apply the Perforin+ 
Granzyme B+ gate to the CD107a+ population to maintain consistency in our gating.     
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Figure 2.7. Frequency of CD8+ T-cells expressing the marker of degranulation CD107a 
and cytoxins perforin and granzyme B split up by HIV antigen (gag, pol, env), and total 
HIV for each study participant pre-immunization and post-immunization. Time-points for 
Post immunization responses for each subject are as follows: 03-001 (gag: wk 18; pol wk 
24; env: no response), 03-002 (gag: wk 18; pol wk 18; env: wk 18), 03-005 (gag: wk 4; pol 
wk 10; env: no response), 03-006 (gag: wk 18; pol wk 10; env: wk 4), 03-007 (gag: wk 10; 
pol wk 10; env: wk 10), 03-008 (gag: wk 18; pol wk 10; env: wk 10), 03-011 (gag: wk 18; 
pol wk 18; env: wk 10), 03-013 (gag, pol, env: no response), 03-015 (gag: wk 8; pol wk 24; 
env: wk 24), 03-016 (gag: wk 8; pol wk 24; env: wk 48), 03-017 (gag: wk 16; pol wk 10; 
env: wk 24). 
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2.4 Discussion 
 In this study we examined the safety and immunogenicity of PENNVAX®-B 
delivered with electroporation in HIV-1 infected individuals who are on stable ART. This 
vaccine was shown to be safe and induced T-cell responses in HIV-uninfected 
individuals, thus we sought to examine if this vaccine could also aid in enhancing cellular 
immune responses in those infected with HIV. For those infected with HIV-1 and on 
stable ART, it would be the goal of a therapeutic vaccine or immuno-therapy, to enhance 
or modify the immune response to aid in controlling the virus with little or no need for 
ART, target the viral reservoir, or eliminate HIV-1 infection164, 165. Additionally, as 
research continues to explore how to better target the viral reservoir, researchers, like 
Archin et al.166 have demonstrated that when they administered the HDAC inhibitor drug, 
vorinostat, to latently infected HIV-positive individuals, the levels of HIV RNA in resting 
CD4+ T cells increase. However, this also suggests the need for HIV-1 infected 
individuals to have the capability of targeting these infected cells, either through ART or 
in combination with a therapeutic vaccine/immuno-therapy that boosts immune functions 
associated with the identification and killing of virally infected cells164, 166. Therefore, 
without understanding how to eliminate these cells, it could leave individuals in a worse 
situation than the one they are in while on ART, such as further depletion of cell subsets 
necessary for avoiding complications from opportunistic infections. Nevertheless, the 
potential for a cure exists, as has been shown by the Berlin patient172. 
 Nonetheless, while previous DNA vaccine strategies have suffered from poor 
immunogenicity and cell-mediated immune responses173, continued research has 
demonstrated that DNA vaccine potency has significantly improved174. Importantly, this 
study shows that a DNA vaccine strategy can be immunogenic and elicit potent cellular 
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responses important against HIV-1 infection. Furthermore, this study supports the use of 
electroporation in delivering DNA-based immuno-therapies.  
 The results presented in this study suggest it is possible to enhance cellular 
immune responses in HIV-1 infected individuals on ART and reveals additional potential 
therapeutic targets. Specifically, this study demonstrated that IFN-! production could be 
enhanced against more than one HIV-1 antigen and in all the individuals in the trial. 
However, the majority of responders responded to pol followed by gag, and env. 
Knowing this, enhancing responses to these antigens may be necessary in order to 
induce a broader cell-mediated response against HIV, which is suggested to be 
important170, 175. Moreover, the responses elicited were demonstrated to be specifically 
due to vaccination, since responses to antigens not present in the vaccine, Nef, were not 
boosted. In addition, the IFN-! responses induced by this vaccine were potent, over 
1000 SFCs, in several individuals. Likewise, this vaccine demonstrated that it is possible 
to use a therapeutic vaccine to elicit IFN-! responses that were indicative of a long-
lasting memory response. Thereby, suggesting that therapeutic vaccine could be used to 
help maintain long-term control of HIV-1 infection.  
  With chronic HIV-1 infection there is a gradual loss in CD8+ T-cells, partly due to 
the loss of CD4+ helper subsets176, 177. In spite of successful ART, these responses are 
not reconstituted leaving these individuals with the inability to respond properly to HIV-1 
infection45, 53. Boosting these CTL responses in HIV-1 infected individuals on ART with a 
therapeutic vaccine or immuno-therapy could lead to reduced need for ART and better 
cell-mediated control of HIV-1 infection. Here, we demonstrate that vaccination with 
PENNVAX®-B could elicit CD8+ CTL responses, specifically the ability to degranulate 
and produce perforin and granzyme B, against HIV-1 antigens. Therefore, this would 
suggest that a therapeutic vaccine against HIV-1 can potentially enhance CD8+ CTL 
44 
cytotoxic capacity, which could lead to better control of infection and delay disease 
progression. Even more, if combined with an anti-latency agent, the ability to kill virally 
infected cells could be boosted. Although several subjects demonstrated an 
enhancement in cytotoxic capacity, not all individuals showed such a response, and one 
individual none at all. On that account, in addition to improving vaccination strategies, 
the need to identify additional therapeutic targets that could further enhance CD8+ CTL 
responses is of interest.  
 As well, as was suggested by the RV144 Trial, eliciting a potent antibody 
response may need to be combined with a cell-mediated therapy to better target HIV-
1168. Additionally, further examining how to improve CD4+ T-cell helper responses will be 
beneficial to both humoral and CTL-mediated responses178. Nonetheless, this study 
demonstrates the need for an immuno-therapy against HIV and expands our 
understanding of eliciting potent cell-mediated immune responses in HIV-1 infected 
individuals on stable ART.  !
Limitations of Study 
 This study demonstrates that a therapeutic vaccine against HIV-1 can be used to 
elicit T-cell mediated immune responses. However, while all the individuals in this study 
demonstrated a positive response via IFN-! as compared to baseline under the set 
definition of response, not all subjects’ exhibited strong responses. For example subjects 
03-016 and 03-017 had IFN-! responses below 500 SFC/106 PBMCs. While statistically 
they are shown to be positive responses, this study cannot address whether responses 
of that low magnitude would be “helpful” responses to HIV-1. In addition, it may be 
necessary to place stricter definitions on a responder in order to ensure a better analysis 
of the impact of vaccination. In addition, other subjects such as 03-006 show higher IFN-
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! responses, but that subject’s cytotoxic response is almost non-existent. Further 
analysis would be necessary to determine why cytotoxic capacity is not enhanced, such 
as the possible effect of T-cell exhaustion. As well, while this study does examine both 
the IFN-! and CD8+ cytotoxic responses, this study may underestimate the overall 
impact on T-cell mediated responses since additional possible functions, such as IL-2 
and TNF-", were not measured in this study. Even more, the analysis of IFN-! 
responses using ELISpot assays limit our findings as to what cells were producing that 
IFN-!. While the goal of this study was not efficacy, studies like this sometimes have 
explored the impact of vaccination through the use of structured treatment interruptions 
of ART to see if control of infection was improved. Studies like those are necessary as 
we continue to investigate what immune correlates are important in a therapeutic setting. 
Additionally, studies like this would benefit from research investigating the timing of 
immunization, specifically, how long after ART/what level of immune reconstitution might 
be necessary to elicit responses important in a therapeutic setting. Finally, this study 
limits our ability to determine if the responses generated by this vaccine are an 
enhancement or boosting of already present responses or eliciting de novo ones.   
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Chapter 3: 
Seroprotection of HIV-Infected Subjects After Influenza 
A(H1N1) Vaccination is Directly Associated with Baseline 
Frequency of Naïve T Cells. 
 
 
 
 
“At the onset of the 2009 influenza season, there was a lot of speculation about whether 
this pandemic would rival the extent of the 1918 pandemic. Fortunately, that was not the 
case, but the lessons learned can be applied to preparations for future pandemics.”        
–Phillip LaRussa (Semin. Respir. Care Med. 2011; Columbia University) 
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3.1 Abstract 
 Individuals infected with HIV-1 are at risk for developing complications from 
influenza infection. Regardless of antiretroviral therapy use, these individuals often have 
blunted vaccine responses. We sought to better understand what factors may impact 
sero-protection to influenza A(H1N1). HIV-1 infected subjects on stable ART received a 
15µg dose of the monovalent, unadjuvanted, inactivated, split virus H1N1 vaccine 
(Novartis). Prior to this study, subjects’ antibody titers were evaluated before receipt of 
the vaccine and at 3 weeks post-immunization. Subjects were then determined to have 
achieved sero-protection (Responders) if by week 3 they had HAI titers that were % 1:40 
and had a %four-fold increase in their antibody titers from baseline. When assessing the 
role of immune activation and cellular phenotypes on sero-protection, we found that 
while the levels of immune activation did not differ between Responders and Non-
responders, Responders had a higher frequency of naïve T-cell populations and lower 
frequency of terminally differentiated T-cell populations. We also assessed the cytokine 
and chemokine profiles of these individuals and compared the serum 
cytokine/chemokine levels to that of healthy HIV-negative controls and between 
Responders and Non-responders. Finally, we assessed the role that age plays in these 
factors associated with responsiveness and found that age was negatively associated 
with the frequency of naïve CD4+ T-cells. Therefore, this study suggests that 
preservation of naïve T-cell populations, through early ART initiation, could impact 
vaccine responses against influenza and other pathogens, especially as this population 
ages. 
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The study in this chapter was conducted in collaboration with others, including Drs. 
Tebas, and Frank. 
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49 
3.2 Introduction 
 In 2009 the novel pandemic H1N1 influenza spread world-wide leading to 
widespread infection and death179. In addition to the severity of this pandemic, seasonal 
influenza can lead to serious illness in young children, the elderly, those with chronic 
infections, and immune-compromised individuals, which include those infected with 
HIV180, 181, 182, 183, 184, 185. Furthermore, the influenza vaccine is safe in those infected with 
HIV186, 187, 188. With ART, the rates of influenza-associated complications are reduced, but 
the rates remain elevated as is seen in other high-risk populations189. 
 In spite of immune reconstitution that should be enough to prevent the 
development of opportunistic infections, HIV-1 infected individuals on ART are shown to 
have poor antibody and memory B-cell responses190. Additionally, poor responses are 
associated with CD4+ T-cell counts and HIV RNA levels191, 192, 193, 194. Even more, it is 
demonstrated that HIV-1 infected individuals often require higher or multiple doses of the 
influenza vaccine to achieve sero-protection195, as similarly seen in other high-risk 
groups196. An early study in HIV-1 infected individuals demonstrated that a 15µg dose of 
the inactivated influenza vaccine induced weaker antibody responses in HIV-infected 
individuals compared to healthy controls, suggesting the need for alternative strategies 
to improve influenza immunization197. Recent studies have demonstrated that 
administering higher doses (60µg)198, 199, multiple doses and/or adjuvanted doses182, 200, 
201, 202 can improve sero-protection, but not all individuals respond regardless.  
Examining the study preceding the one in this chapter, demonstrated that HIV-1 
individuals on ART do not all achieve sero-protection following H1N1 influenza 
vaccination203. Furthermore, despite ART, the durability of antibody responses following 
influenza vaccination is not as durable compared to HIV-uninfected controls204. 
Therefore the purpose of this study was to further understand what HIV-1 associated 
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dysregulation may affect the ability of these individuals to respond to influenza 
vaccination. While we do not examine the direct impact of HIV-associated dysregulation 
on B-cells, this study reinforces the impact on CD4+ T-cells can have impact on humoral 
responses and thus response to influenza vaccination.  
HIV-1 infection leads to an imbalanced cytokine/chemokine, environment, and 
induces changes in apoptosis, exhaustion, and senescence10, 205. The altered 
cytokine/chemokine environment was shown to impact the severity of pandemic H1N1 
influenza infection206. Thus, a dysregulated cytokine/chemokine milieu could also place 
HIV-1 infected individuals at risk, but understanding the role this environment plays can 
reveal possible targets to improve protection in these subjects. Also, regardless of ART, 
HIV-1 infected individuals maintain elevated levels of T-cell activation31. These levels of 
immune activation are associated with disease progression and are suggested to 
contribute to immune dysfunction14. Hence, it is possible that elevated levels of immune 
activation could contribute to blunted responses to vaccines. In addition, while the 
development and use of ART has improved the survival of individuals living with HIV-117, 
as this population ages their immune system ages as well, thereby contributing to 
defects of the immune system, a concept called “inflammaging.” This concept suggests 
that the immune systems of those infected with HIV-1 exhibit changes reminiscent of the 
elderly207. During physiological aging, there is progressive thymic involution, and in turn 
deceases in naïve T-cell numbers and reduced T-cell function207, 208. These changes are 
also seen in those infected with HIV and result in an accumulation of terminally 
differentiated immune cells, which can impact antigen responsiveness3.  Regardless, 
studies have demonstrated the importance of vaccinating the elderly against influenza to 
reduce complications and co-morbidities209, 210. And as the CDC211 suggests, giving the 
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influenza vaccine to those infected with HIV-1 is also necessary to protect these 
individuals212, 213.   
As a result, we hypothesize that in order to better improve protection in HIV-1 
infected individuals, it is necessary to understand what factors, such as immune 
activation, cytokine/chemokine dysregulation, cellular phenotypes, and aging, can 
contribute to lack of sero-protection and help identify prospective therapeutic targets to 
aid in designing better vaccination strategies against influenza and other pathogens.   
 
3.3 Results 
i. Study Design 
This research is a follow-up to the study previously presented by Tebas et al.203.  
The goal of that study was to examine the safety and immunogenicity of the 
recommended H1N1 vaccine (Novartis, Basel, Switzerland). HIV-1 infected subjects that 
were over the age of 18 and had an indication to receive the H1N1 vaccine were 
included in the study. Subjects were excluded if they had a known allergy to eggs or 
other components of the vaccines, had previous severe reactions to prior immunization 
to seasonal flu, or had known cases of H1N1 influenza during Spring 2009. Additionally, 
if subjects had received any licensed live vaccines 4 weeks prior to study entry, or 
inactivated vaccines prior to entry into the study. Participants were also excluded if they 
were currently receiving any other experimental treatments, systemic chemotherapy, 
steroids, immune-modulators, or had a history of Guillain-Barre syndrome.  
A total of 120 participants were included in the primary study by Tebas et al.203 
and provided informed consent. For this follow-up study, the goal was to examine pre-
vaccination baseline characteristics that can serve as predictors of their vaccine 
response. Forty-six subjects had enough frozen peripheral blood mononuclear cell 
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samples available for analysis in this study. These 46 subjects had baseline 
hemagglutination inhibition (HAI) titers of <1:40 and were on ART. Subjects’ median age 
was 48 years, with a range of 26-77 years of age; 69.6% were male, 30.4% were 
female; 63% identified as Black/African-American, 10.9% were Hispanic/Latino, 23.9% 
were white, and 2.1% identified as Asian/Pacific Islander. These subjects had an 
average CD4+ T-cell count of 542 ± 306.8 cells/µl, an average nadir CD4+ T-cell count 
of 193 ± 187.2 cells/µl, and HIV RNA loads were <400 copies/mL in 90% of the subjects, 
and below the limit of detection in 85% of the subjects (Table 3.1).  
Participants received a single 15µg intra-muscular dose of the monovalent 
unadjuvanted, inactivated, split virus H1N1 vaccine. As depicted in figure 3.1, each 
participant had blood collected and baseline studies performed prior to immunization. 
Following 21-28 days after vaccination, blood was collected and serological responses 
to the vaccine were evaluated by Tebas et al.203. They examined antibody titers of the 
120 subjects using an HAI assay at Bioqual, Inc., as described previously by Kendal et 
al.214. Subjects were classified as sero-protected and Responders to the vaccine if at 
week 3 post-immunization their HAI titers were %1:40 and increased at least 4-fold 
higher than baseline, otherwise subjects not meeting these requirements were 
considered Non-responders. For the purpose of this study 27 subjects fit into the 
classification of Responder and 19 into the Non-responder classification. 
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Table 3.1. Demographic and immunologic characteristics of study participants.  
 
Characteristic   
Subjects 
(n=46) 
Age, y     
Median  48 
   Range  26-77 
Sex, n (%)     
   Male  32 (69.6) 
   Female  14 (30.4) 
Race, (%)     
   White  23.9 
   Black or African American  63 
Ethnicity, (%)     
   Hispanic or Latino  10.9 
   Non-Hispanic or Latino  89.1 
CD4+ T-cell count at screening, cells/µl   
   Mean  544 
   Range   71-1396 
Nadir CD4+ T-cell count, cells/µl   
   Mean  193 
   Range  1-831 
HIV-1 viral load at screening,%     
<400 copies/ml  90% 
Below Limit of quantification   85% 
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Figure 3.1. Study and immunization timeline. Diagram depicts time-points of 
immunization, blood collection, and HAI assays. 
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ii. T-cell Activation 
We hypothesized that the baseline levels of immune activation would affect the 
ability of subjects to achieve Responder status, since immune activation is a negative 
predictor of HIV-1 disease progression and contributes to cell turnover 9, 10. In order to 
evaluate the levels of immune activation we used multi-parameter flow cytometry to 
examine the expression of the activation markers CD38 and HLA-DR on the surface of 
T-cells prior to vaccination. The diagram in figure 3.2 depicts the gating strategy used to 
examine expression of the activation markers.  
Using this strategy we compared the expression of CD38 and HLA-DR on CD4+ 
and CD8+ T-cells between Responders and Non-responders. We found that baseline 
expression levels of CD38+ HLA-DR+ CD4+ did not differ between Responders and 
Non-responders (1.56%±1.63% [n=27] vs. 1.95%±2.87% [n=19]; p=0.688; figure 3.3). 
Likewise, the expression levels of CD38+ HLA-DR+ CD8+ T-cells also did not differ 
between Responders and Non-responders (1.91%±1.79% [n=27] vs. 2.3%±3.63% 
[n=19]; p=0.8409; figure 3.3). This then suggests that baseline levels of activation do 
not play a significant role on the response to the H1N1 influenza vaccine.  
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Figure 3.2. Example layout of gating strategy. First, gating for the live CD3+ T-cell 
population, we then gate for our CD4+ and CD8+ subsets. The CD4+ and CD8+ T-
cell subsets are then gated for their expression of the activation markers CD38 and 
HLA-DR and for their memory phenotype populations (CD27, CD45RO). 
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Figure 3.3. Mean percentages of activated (CD38+ HLA-DR+) A) CD4+ T-cells 
(1.56%±1.63% [n=27] vs. 1.95%±2.87% [n=19]; p=0.7) and B) CD8+ T-cells 
(1.91%±1.79% [n=27] vs. 2.3%±3.63% [n=19]; p=0.8) among Responders and Non-
Responders. 
A B !
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iii. T-cell Differentiation Phenotypes 
 Research on HIV-1 infection has shown that chronically infected individuals 
exhibit an accumulation of terminally differentiated T-cells and have reduced 
regenerative potential10, 14. We wanted to examine whether the presence/lack of certain 
T-cell differentiation subsets could impact sero-protection to H1N1 in HIV-infected 
individuals. Using the gating strategy in figure 3.2 we examined the expression of CD27 
and CD45RO on the surface of CD4+ and CD8+ T-cells. We classified CD27+CD45RO- 
T-cells as naïve, CD27+CD45RO+ T-cells as central memory, CD27-CD45RO+ T-cells 
as effector memory, and CD27-CD45RO- T-cells as terminally differentiated effectors. 
 We found that Responders and Non-responders differed in their T-cell 
differentiation phenotype profiles. Specifically, Responders had a significantly higher 
baseline percentage of naïve (CD27+ CD45RO-) CD4+ (50.2%±23.1% [n=27] vs. 
33.5%±23.1% [n=19]; p=0.02; figure 3.4A) and CD8+ T-cells (41.5%±17.9% [n=27] vs. 
23.4%±17.4% [n=19]; p=0.001; figure 3.4C) as compared to the lower frequency 
observed in Non-responders. Additionally, we found that subjects classified as Non-
responders had an increased baseline percentage of terminally differentiated (CD27-
CD45RO-) CD4+ (3.2%±3.7% [n=27] vs. 11.3%±14.4% [n=19]; p=0.007; figure 3.4B) 
and CD8+ T-cells (26.1%±12.3% [n=27] vs. 40.2%±20.1% [n=19]; p=0.005; figure 3.4D) 
compared to a lower frequency observed in Responders. These findings suggest the 
possible importance of conserving the regenerative potential of T-cells in HIV-1 infected 
individuals.  
 When further examining potential predictors of response, which included viral 
load, baseline CD4+ T-cell counts, CD4+ T-cell nadirs, CD4+ and CD8+ naïve and 
terminally differentiated T-cells. We found that the CD4+ T-cell nadirs of the subjects 
were positively associated with the pre-immunization baseline CD4+ naïve (CD27+ 
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CD45RO-) T-cells (n=46; R2=0.141; p=0.01; figure 3.5). Thereby further illustrating the 
importance of preserving this T-cell subset. 
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Figure 3.4. PBMCs were stained for markers of differentiation (CD27, CD45RO) and 
analyzed via flow cytometry. Mean baseline frequencies of A) naïve (CD27+ CD45RO-) 
CD4+ T-cells (50.2%±23.1% [n=27] vs. 33.5%±23.1% [n=19]; p=0.02), B) terminally 
differentiated (CD27-CD45RO-) CD4+ T-cells (3.2%±3.7% [n=27] vs. 11.3%±14.4% [n=19]; 
p=0.007), C) naïve (CD27+CD45RO-) CD8+ T-cells (41.5%±17.9% [n=27] vs. 23.4%±17.4% 
[n=19]; p=0.001), and D) terminally differentiated (CD27-CD45RO-) CD8+ T-cells 
(26.1%±12.3% [n=27] vs. 40.2%±20.1% [n=19]; p=0.005) among Responders and Non-
Responders.  
A B 
D C 
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Figure 3.5. Multivariate regression analysis examining linear regression between the 
baseline frequency of naïve (CD27+ CD45RO-) CD4+ T-cells and the nadir CD4+ T-
cell count (n=46; R2=0.141; p=0.01). 
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iv. Cytokine and Chemokine Profiles 
 As discussed before, HIV-1 infected subjects exhibit an imbalanced cytokine and 
chemokine environment as compared to their healthy HIV-uninfected counterparts206205. 
We thus examined the cytokine and chemokine profiles of the subjects in this study and 
compared them to the profiles of healthy HIV-negative subjects using a Luminex assay.  
 When comparing the cytokine/chemokine profiles of these subjects to that of 
healthy controls we found that the HIV-1 infected subjects had significantly lower serum 
levels of Th1 type cytokines that included IFN-! (203.4±369.4 pg/ml [n=46] vs. 
434.2±410.2 pg/ml [n=10]; p=0.0159), IFN-"2 (167.1±562.4 pg/ml [n=46] vs. 
352.5±727.3 pg/ml [n=10]; p=0.0166), TNF-# (52.01±119.6 pg/ml [n=46] vs. 241.4±281.5 
pg/ml [n=10]; p=0.0218), IL-10 (7.56±10.52 pg/ml [n=46] vs. 76.22±117.3 pg/ml [n=10]; 
p=0.0019); Th2 type cytokines: IL-5 (28.9±108.3 pg/ml [n=46] vs. 52.0±118.9 pg/ml 
[n=10]; p=0.0142); and others such as VEGF (760.8±874.2 pg/ml [n=46] vs. 1576±1267 
pg/ml [n=10]; p=0.0197) and IL-1# (5.8±17.1 pg/ml [n=46] vs. 11.4±9.5 pg/ml [n=10]; 
p=0.0028). On the other hand, the HIV-1 infected subjects also demonstrated elevated 
serum levels of the chemokines MIP-1# (146.5±216.6 pg/ml [n=46] vs. 36.7±29.4 pg/ml 
[n=10]; p=0.036) and IP-10 (531.0±364.1 pg/ml [n=46] vs. 205.3±62.2 pg/ml [n=10]; 
p=0.0105), as well as elevated serum levels of IL-1" (1046±1451 pg/ml [n=46] vs. 
23.1±23.1 pg/ml [n=10]; p=0.0009; Table 3.2).  
 Furthermore, in order to examine if the dysregulated cytokine/chemokine 
environment plays a potential role in sero-protection after H1N1 vaccination, we 
compared the serum cytokine and chemokine levels between Responders and Non-
responders. We found that individuals who achieved sero-protection, otherwise known 
as Responders, had higher serum levels of IFN-"2 (272.6±741.4 pg/ml [n=27] vs. 
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30.03±57.0 pg/ml [n=19]; p=0.0493), IL-10 (10.7±11.9 pg/ml [n=27] vs. 2.3±3.9 pg/ml 
[n=19]; p=0.0009), and IL-6 (90.9±162.2 pg/ml [n=27] vs. 6.7±8.5 pg/ml [n=19]; 
p=0.0244) compared to lower serum levels observed in Non-responders (Table 3.3). 
These findings suggest that the pre-vaccination cytokine and chemokine environment 
could impact responsiveness to vaccination, and thus sero-protection.  
 Lastly, we examined whether pre-vaccination baseline serum 
cytokine/chemokine levels were related to factors that were associated with sero-
protection above. Among the cytokine and chemokines that were altered in the HIV-1 
infected participants in this study, we found a trending negative association with higher 
serum levels of IP-10 and the baseline percentage of naïve (CD27+ CD45RO-) CD8+ T-
cells. Suggesting a role for this chemokine, IP-10, on the preservation of important CD8+ 
T-cell subsets (figure 3.6).  
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Table 3.2. Cytokine and Chemokine profiles of HIV-1 infected individuals in this study 
and of healthy HIV-negative controls measured using a Luminex assay.  
  
Immunological 
Marker 
Healthy Control (conc. 
pg/ml)  
HIV+ on ART 
(conc. pg/ml) p-value 
Primarily Th1 IL-12p40 210.5±351.1 102±144.6 0.3112 
  IL-12p70 425.4±654.6 143±414.7 0.0878 
  IFN-! 434.2±410.2 203.4±369.4 0.0159 
  TNF-" 10.96±7.172 22.28±38.15 0.4101 
  TNF-# 241.4±281.5 52.01±119.6 0.0218 
  IL-10 76.22±117.3 7.563±10.52 0.0019 
Primarily Th2 IL-4 289.4±325.5 115.7±104.7 0.0771 
  IL-5 52±118.9 28.88±108.3 0.0142 
  IL-6 11.6±5.89 61.12±131.9 0.9731 
  IL-13 278.5±295.2 176.8±298.4 0.1243 
Growth Factors IL-2 65.32±123.9 18.15±44.36 0.1238 
  IL-3 14.17±27.21 25.73±61.87 0.6515 
  IL-7 34.57±79.28 27.47±67.37 0.5852 
  IL-15 44.25±94.63 7.310±5.342 0.1269 
  G-CSF 53.17±58.06 205.7±490.7 0.1112 
  GM-CSF 30.22±26.62 74.24±152.2 0.1069 
  VEGF 1576±1267 760.8±874.2 0.0197 
  EGF 153.4±76.65 232.6±229.0 0.6303 
Chemokines MIP-1" 38.15±24.18 253.5±705.6 0.2057 
  MIP-1# 36.73±29.35 146.5±216.6 0.036 
  IL-8 138.4±93.94 200±258.4 0.661 
  MCP-1 534.5±126.4 593.3±246.7 0.4689 
  Eotaxin 335.8±244.4 184.1±91.7 0.0642 
  IP-10 205.3±62.2 531.0±364.1 0.0105 
Other IL-17A 234.1±207.4 10.3.2±159.8 0.0303 
  IL-1Ra 104.2±85.84 367.3±1040 0.228 
  IL-1" 23.09±23.05 1046±1451 0.0009 
  IL-1# 11.41±9.47 5.79±17.05 0.0028 
 IFN-"2 352.5±727.3 167.1±562.4 0.0166 
     
 
65 
 
Table 3.3. Cytokine and Chemokine profiles of study participants classified as 
Responders compared to those individuals classified as Non-Responders measured 
using a Luminex assay. 
  
Immunological 
Marker 
Responder (conc. 
pg/ml) 
Non-Responder 
(conc. pg/ml)  p-value 
Primarily Th1 IL-12p40 119.2±159.8 39.06±27.71 0.4167 
  IL-12p70 202.3±526.1 61.92±154.3 0.6127 
  IFN-! 257.9±440.5 121.6±210.9 0.3913 
  TNF-" 29.8±48.67 11.59±3.572 0.6717 
  TNF-# 70.46±146 11.4±14.77 0.0697 
  IL-10 10.74±11.97 2.263±3.893 0.0009 
Primarily Th2 IL-4 112.3±90.98 128.1±171.9 0.8935 
  IL-5 48.09±139.2 1.579±2.534 0.0652 
  IL-6 90.86±162.2 6.684±8.526 0.0244 
  IL-13 220.2±350.5 82.7±100.3 0.5107 
Growth Factors IL-2 25±54.67 6.15±9.677 0.1326 
  IL-3 31.98±68.54 0.735±0.3323 0.1904 
  IL-7 29.44±70.23 24.68±14.88 0.6714 
  IL-15 8.133±5.531 4.843±4.437 0.3316 
  G-CSF 295.9±631.1 86.92±133.5 0.6102 
  GM-CSF 83.14±154.8 60.02±152.1 0.6334 
  VEGF 878.5±1054 593.4±506.5 0.828 
  EGF 278.6±260.8 167.1±158.7 0.0579 
Chemokines MIP-1" 206.9±688.0 329.2±749.8 0.5514 
  MIP-1# 191.4±262 82.75±104.2 0.0942 
  IL-8 202.4±260.3 196.5±262.7 0.8235 
  MCP-1 577.2±248.9 616.2±248.5 0.4892 
  Eotaxin 193.3±99.53 171.1±80.05 0.4267 
  IP-10 548.3±404.5 506.4±306.8 0.9112 
Other IL-17A 130.4±190.5 64.5±93.48 0.3842 
  IL-1Ra 443.4±1088 265.9±993.3 0.2363 
  IL-1" 925.6±1309 1529±2207 0.516 
  IL-1# 7.953±21.65 2.906±7.362 0.2626 
 IFN-"2 272.6±741.4 30.03±57 0.0493 
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Figure 3.6. Linear regression examining the association between baseline pre-
vaccination serum levels of IP-10 (pg/ml) and frequency of naïve (CD27+ CD45RO-) 
CD8+ T-cells (n=46; Spearman r= -0.2895; p=0.051). 
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v. Age 
 Knowing that age189, 215 can impact the severity of influenza infection and 
responsiveness to vaccination, we further examined a possible role of age in sero-
protection to H1N1 influenza. When examining the relationship between age and the 
predictors of response, age was negatively associated with the frequency of naïve 
(CD27+ CD45RO-) CD4+ T-cells (n=46; R2=-0.182; p=0.003; figure 3.7). Even more, we 
also found that there was a trend towards higher serum IP-10 levels and older age 
groups (Group 1 [Age 22-34]: n=6, 363.2±180.5 pg/ml; Group 2 [Age: 35-44]: n=12, 
420.5±388.0 pg/ml; Group 3 [Age: 45-54]: n=13, 481.4±195.7 pg/ml; Group 4 [Age: 55+]: 
n= 14, 590.0±293.7; p=0.089; figure 3.8). These findings suggest a potential 
confounding effect of age in the role of sero-protection in HIV-1 infected individuals 
against influenza vaccination.  
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Figure 3.7. Multivariate regression analysis examining the linear regression between 
age of the study participants and baseline frequency of naïve (CD27+ CD45RO-) 
CD4+ T-cells (n=46; R2= -0.182; p=0.003).  
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Figure 3.8. Serum IP-10 levels of study participants grouped into cohorts by age 
(Group 1 [Age 22-34]: n=6, 363.2±180.5 pg/ml; Group 2 [Age: 35-44]: n=12, 
420.5±388.0 pg/ml; Group 3 [Age: 45-54]: n=13, 481.4±195.7 pg/ml; Group 4 [Age: 
55+]: n= 14, 590.0±293.7; p=0.089). A one way ANOVA was used. 
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3.4 Discussion 
 The previous findings by Tebas et al.203, demonstrate a recurring concern in HIV-
1 infected individuals. Despite receipt of ART, it appears that not all individuals respond 
to the standard recommended dose of the H1N1 influenza vaccine. While the definition 
of Responder in this study is dependent on humoral responses, this study reinforces the 
importance of CD4+ T-cell help in responses to influenza. Along those lines, the findings 
show a relationship in the baseline frequency of naïve (direct association) and terminally 
differentiated (inversely associated) T-cells with sero-protection after immunization with 
the recommended dose of H1N1 vaccine. Importantly, the findings in this study 
demonstrate firstly the potential need to preserve the naïve T-cell populations in those 
infected with HIV-1 and raises the question about the timing for the initiation of 
antiretroviral therapy. We see here that the amount of immune reconstitution that occurs 
in those infected with HIV after ART initiation, can possibly still leave these individuals at 
risk for opportunistic infections if the immune reconstitution is not “sufficient” enough. As 
shown in this study, the pre-ART CD4+ T-cell nadir was associated with the frequency of 
naïve CD4+ T-cells post-ART, thereby suggesting the gravity of immune reconstitution in 
these individuals.  
On the other hand, we had hypothesized that the level of T-cell activation would 
be associated with sero-protection, since levels of T-cell immune activation are 
associated with negative outcomes in regards to HIV-1 disease progression9, 216. 
However, we saw no significant association with the levels of baseline T-cell immune 
activation and sero-protection. When examining predictors of vaccine response using a 
logistic regression model, we found that the independent predictors of response were 
the baseline frequency of naïve CD4+ T-cells (n=46; p=0.024; R2=0.111) and terminally 
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differentiated CD8+ T-cells  (n=46; p=0.0004; R2=0.251). While we saw no direct impact 
of T-cell activation on vaccine responses, it is still possible that levels of immune 
activation could be one potential factor contributing to the loss or accumulation of the T-
cell populations, CD4+ naïve T-cells and CD8+ terminally differentiated cells, important 
for vaccine responses. In fact, it has been suggested that immune activation can 
contribute to the loss of an individual’s naïve CD4+ T-cell population216, 217, 218. By the 
same token, loss of the CD4+ T-cell population could contribute to issues in the 
maintenance of the CD8+ T-cell population, which are important for control of HIV-1 
infection219. While CD8+ T-cell responses have been shown to play roles in influenza 
infection220, studies demonstrate the important roles for CD4+ T-helper cells in 
promoting B-cell responses and antibody production39. Early depletion studies 
demonstrated that alone CD4 or B-cells were not enough to clear certain influenza 
infections220. Thereby suggesting the need for not only humoral immunity, but also an 
important role for the help provided by CD4+ helper cells in the humoral response 
against influenza. As well, as is seen in studies of influenza in HIV-1 infected individuals 
influenza-specific humoral responses were shown to be associated with CD4 counts186. 
These findings along with the ones in this study reinforce the importance of conserving 
CD4+ T-cells in HIV-1 infected individuals in order to maintain humoral immunity, which 
is important in influenza infection. Furthermore, recent studies have demonstrated the 
important role that T-follicular helper cells play in influenza infection. These cells have 
been shown to be important in supporting IgG production and expansion of B-cells 
during the germinal center reaction221. In regards to HIV-1 infection, the presence of T-
follicular helper cells are shown to help elicit humoral responses similar to healthy 
individuals responding to H1N1 infection, while, non-responders did not exhibit changes 
in the expansion of tfh cells. So in addition for the need to understand how to preserve 
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CD4+ T-cells, including tfh cells, the study in this chapter reinforces the need to also 
maintain the naïve CD4+ T-cell population, which can play an important role in de novo 
responses to influenza. 
 In addition as we observed in the study in chapter 4, we found that the cytokine 
and chemokine environment of the individuals infected with HIV-1 is dysregulated 
compared to healthy controls. These findings support that despite ART, HIV-1 infected 
individuals’ cytokine levels do not return to normal14.  The subjects in this study exhibit a 
reduced serum level of cytokines important in the antiviral response such as IFN-!, 
which is important in cellular and humoral immune responses in the respiratory tract of 
those infected with influenza222. On the other hand, we also observed that the serum 
levels of the pro-inflammatory chemokine, IP-10 were high in these HIV-1 infected 
individuals. Previous studies have discussed that HIV-1 infected individuals have issues 
with H1N1 virus clearance related to elevated levels of IP-10150. In this study we found 
an association between higher serum levels of IP-10 and lower baseline frequency of 
naïve CD8+ T-cells. This association can be concerning, especially, since it has been 
demonstrated that the maintenance of a healthy T-cell population is important for T-cell 
mediated help that can aid in avoiding issues with influenza virus infection when 
antibodies do not provide sterilizing immunity223.  
 In regards to sero-protection, the cytokines IFN-"2, IL-10, and IL-6 were found to 
be elevated in the subjects classified as Responders. Elevated IL-6 levels are shown to 
be important in the protection against H1N1 infection by promoting survival of innate 
immune cells224. Furthermore, in mice infected with influenza, blockade of the IL-10 
receptor was associated with higher rate of death225, 226. Therefore, elevated levels of IL-
10 in Responders could serve as a mechanism to help control excessive inflammation 
and increased lung injury observed during severe influenza infection. Additionally, 
73 
research by Sandler et al.227 has suggested a role for IFN-"2 in regulating HIV acute 
infection, antiviral activity, and cell death early in infection as compared to late infection. 
Thus, low IFN-"2 levels in Non-responders could affect the ability of these individuals to 
control infection prior to ART initiation and in turn lead to more immune damage. 
Furthermore, IFN-"2 is shown to enhance B cell responses263, so higher levels in 
Responders would suggest a role in enhancing influenza vaccine responsiveness. This 
damage could then leave these individuals with the inability to properly achieve sero-
protection. Hence, examining potential cytokines and chemokines associated with sero-
protection and influenza viral clearance can elucidate relevant targets to aid in avoiding 
more severe infection in those infected with HIV-1.  
 However, the cytokine and chemokine environment in HIV-1 infected individuals 
may not be the only confounding factor that could impact sero-protection against 
influenza infection. HIV-1 infected individuals are shown to exhibit premature 
immunosenescence and persistent ongoing inflammation characteristic of older HIV-
negative individuals. This phenomenon occurs even with effective ART10. This 
premature aging of the immune system is associated with issues in CD4+ T-cell immune 
reconstitution and development of co-morbidities, such as cancer and cardiovascular 
disease10, 228. Elderly HIV-negative individuals have a reduced number of naïve T-cells229 
and as those infected with HIV-1 continue to survive longer, age will play a role in the 
ability of medical professionals to protect these individuals from opportunistic infections, 
i.e. influenza infection. And as has been shown, cell-mediated responses to influenza 
are important in helping humoral immunity to influenza infection223. As we observed in 
this study, age was negatively associated with the baseline frequency of naïve CD4+ T-
cells, therefore elder HIV-1 infected individuals may maintain issues in achieving sero-
protection after immunization. Even more, we saw a trending increase in the serum 
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levels of IP-10 with age, suggesting the possibility of increased issues with influenza 
viral clearance as HIV-1 infected individuals continue to live longer.  
 Finally, the CDC already offers immunization recommendations for elderly HIV-
negative individuals230. Therefore, for HIV-1 infected subjects, the administration of these 
vaccines at an earlier age may be necessary in order to avoid non-responsiveness due 
to deterioration of their immune systems. Proactively, it may also be necessary to initiate 
ART earlier, thereby leading to better preservation of naïve cell subsets and lead to 
improved immune reconstitution. Additionally, response to vaccination in those infected 
with HIV-1 can potentially be used as a surrogate marker of immune reconstitution and 
successful treatment with ART.   
 
!
Limitations of Study 
 This study elucidates potential correlates associated with better responsiveness 
to H1N1 vaccination. However, this study is limited in that it examines only the potential 
role that the T-cell mediated immunity may play in vaccine responsiveness. While T-cells 
are shown to also be important in the response against influenza, this study does not 
investigate possible correlates associated with the humoral arm of immunity that may be 
involved in better vaccine responses to influenza, especially in HIV-1 infected 
individuals. This study is also limited in that of the 120 subjects in the original study, only 
46 of those subjects had sufficient samples for additional assays, thereby potentially 
affecting or underestimating additional possible correlates of vaccine responsiveness. 
Furthermore, while age is a possible counfounding factor in regards to influenza 
vaccination, our study may be limited in estimating the impact of age on responsiveness 
since the individuals in this study were younger than most studies examining age.   
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CHAPTER 4: 
High IP-10 Levels Decrease T-cell Function in HIV-1 
Infected Individuals on ART. 
 
“Why a chemoattractant seemingly so potent as CXCL10 is elevated in patients who fail 
to clear HCV has been paradoxical.”  
–Edgar D. Charles (J. Clin. Invest. 2011; Rockefeller University) 
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4.1 Abstract 
 Even with effective antiretroviral therapy, it is observed that HIV-1 infected 
individuals have an imbalanced cytokine and chemokine environment. Changes in 
systemic cytokines and chemokines can alter immune responses of these individuals. 
One such chemokine, IP-10 is associated with the pathogenesis of several diseases in 
addition to HIV-1 infection. Specifically, we found elevated serum IP-10 levels in two 
cohorts of HIV-1 infected subjects on ART compared to healthy HIV-negative individuals. 
Using a series of in vitro studies we demonstrate that PBMCs exposed to elevated levels 
of IP-10 exhibit a significant decrease in the number of cells capable of secreting IFN-!, 
as well as other cytokines, when stimulated with recall antigens. Furthermore, we found 
that elevated levels of IP-10 led to decreased calcium signaling and phosphorylation of 
the MAP Kinase p38. However, we show that production of IFN-! and other cytokines, 
cytotoxic capacity, and proliferative capacity can be enhanced using a neutralizing 
antibody against IP-10. Additionally, our findings demonstrate a potential mechanism of 
action for elevated levels of IP-10. Specifically, elevated IP-10 levels may exert its effect 
through blocking of the CXCR3 receptor and demonstrates a role for the amino-
peptidase CD26 in processing IP-10 to it’s antagonistic for, thereby eliciting an impact on 
T-cell function. Our findings therefore suggest the need of IP-10 modulating agents for 
HIV-1 infected subjects on ART in order to enhance T-cell responses to vaccination and 
HIV-1.  
  
Citation: Ramirez, LA, Arango, TA, Thompson, E, Naji, M, Tebas, P, Boyer, JD. High IP-
10 Levels Decrease T-cell Function in HIV-1 Infected Individuals on ART. J. Leukocyte 
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4.2 Introduction 
 With a lack of an effective vaccine or cure against HIV-1, research continues in 
the development of a vaccine or immune-therapy that can help boost immune responses 
in HIV-1 infected individuals. With HIV-1 infection, one of the many changes to the 
immune system of infected individuals is the obvious change in the production and 
secretion of cytokines and chemokines231, 232. However, these changes are not fully 
reversed with ART101, 231, 233. Findings in this study and others demonstrate specifically 
an increased level of the pro-inflammatory chemokine IP-10/CXCL10 in both untreated 
and ART treated HIV-1 infected individuals 133, 134. While IP-10 is a double-edged sword 
of sorts depending on the disease, there is evidence that this chemokine’s role in both 
untreated and treated HIV-1 infections is more injurious than helpful.  
 Aside from IP-10’s role in the pathogenesis of several other diseases, its role in 
HIV-1 infection is not any more positive. During untreated HIV-1 infection, IP-10’s 
interaction with HIV-1 proteins, such as Tat and Nef, show IP-10’s role in promoting HIV-
1 replication and neuronal cell death134,140, 143. Furthermore, IP-10 is associated with HIV-
1 disease progression in both progressors and HIV-1 immune controllers12, 137. These 
associations, make sense, IP-10 is involved in the chemotaxis of activated immune cells, 
this could lead to potential recruitment of more activated lymphocytes and in turn more 
HIV-1 targets. In relation to ART, IP-10 has also been associated with immunological 
treatment failure109. Too, it is suggested that having lower mucosal IP-10 may be 
protective against acquisition of HIV-1 infection138. Hence, the findings and results 
presented in the study in this chapter demonstrate the importance of recognizing IP-10’s 
impact on T-cell function in HIV-1 infected individuals, and in particular to this study, the 
effect of IP-10 specifically in ART treated individuals.  
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 IP-10/CXCL10 is a pro-inflammatory chemokine and a member of the CXCR3 
family of ligands, which include MIG/CXCL9 and I-TAC/CXCL119. IP-10’s main function 
is to recruit immune cells to sites of inflammation126. These signals have been shown to 
be dominant over TCR signals127. Thereby suggesting a potential role for IP-10 in the 
regulation of T-cell function. Additionally, recent studies of HCV infection demonstrate a 
conflicting role for IP-10. It would be expected that a chemokine involved in the 
recruitment of immune cells to the sites of infection would lead to better prognosis in 
treatment success for HCV, however, the opposite is shown130. Not only, is IP-10 
upregulated during chronic HCV infection, it also serves as a negative predictor of 
response to HCV therapy130. Therefore, we hypothesized that elevated levels of IP-10 
during treated HIV-1 infection could play a role in affecting normal T-cell function, 
specifically those functions, IFN-! production, cytotoxic and proliferative capacity, 
associated with better control of HIV-1 infection53. Finally, the study in this chapter 
explores a potential mechanism of action through which IP-10 can impact T-cell function 
in HIV-1 infected individuals on ART.  
 
4.3 Results 
 i. Study Design 
 Sera, PBMCs, and isolated CD4+ and CD8+ T-cells from healthy HIV-negative 
subjects, HIV-1 infected untreated subjects, and HIV-1 infected subjects on stable ART 
were obtained from the University of Pennsylvania’s Human Immunology Core and 
Center for AIDS research. Subjects ranged in age from 20-55 years of age with and 
average age of 31 years. HIV-1 infected subjects on ART were well controlled with viral 
loads less than 50 copies/mL, average current CD4+ T-cell counts over 400 cells/µl and 
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CD4+ nadirs over 200 cells/µl. HIV-1 infected untreated subjects had a median viral load 
of 16,511 copies/mL. 
Schematic of cell culture treatment is depicted in figure 4.1. PBMCs, and 
isolated CD4+ and CD8+ T-cells were cultured in media alone (RPMI 1640 with L-
glutamine + 10% FBS and 1% streptomycin/penicillin) or media with one of the rhIP-10 
doses (500, 10,000, or 100,000pg/ml) or Anti-IP-10 neutralizing antibody (1µg/ml) for 24 
hours. These cells were then stimulated with viral antigens or anti-CD3 and used in the 
ELISpot, flow cytometry, Luminex, and Ca2+ flux assays. To determine if IP-10 treatment 
impacted cell viability we determined post IP-10 treatment viability and compared it to 
cell viability in media alone. Average cell viability post treatment with IP-10 was 
95.1±3.3% and 89.2±3.2% for the healthy HIV-negative and HIV-infected on ART 
samples, respectively (figure 4.2).  
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Figure 4.1. Diagram describing the in vitro treatment of immune cell cultures with 
recombinant human IP-10 or anti-IP-10 neutralizing antibody prior to use in 
immunological assays. 
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Figure 4.2. Top panel: Example of CD3+ lymphocyte Live/Dead Violet mean 
fluorescence intensity in response to treatment with media alone or 500pg/ml of IP-
10. Middle Panel: Example of total PBMC Live/Dead Violet mean fluorescent 
intensity in response to treatment with media alone or 500pg/ml of IP-10. Red line 
represents treatment with media alone, while the blue line represents treatment with 
IP-10. Bottom Panel: Diagram listing cell viability pre- and post-treatment with media 
alone or 500pg/ml in HIV-negative subjects and HIV-1 infected subjects on ART. 
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ii. HIV-1 infected subjects have high serum IP-10 levels 
 Using a multi-plex Luminex assay we examined the cytokine and chemokine 
profiles of HIV-1 infected subjects on stable ART and compared it to the profiles of 
healthy HIV-negative individuals. We found that the HIV-1 infected individuals on ART 
exhibited significantly lower levels of IL-10, IL-5, IL-13, IL-15, IL-1RA, and IL-1# as 
compared to healthy HIV-negative controls. While we see that the HIV-1 infected 
individuals have lower serum levels of Th2 cytokines, specifically, IL-5 and IL-13, we 
also see that these individuals have significantly lower levels of cytokines important in 
immune regulation, anti-inflammation, and maintenance and growth of cells, that is IL-
10, IL-15, and IL-1 receptor antagonist. What stood out however, was that these 
individuals exhibited significantly higher serum levels of the pro-inflammatory chemokine 
IP-10 (Table 4.1) Furthermore, we found that untreated HIV-1 infected subjects had 
significantly higher levels of IP-10 compared to healthy uninfected controls. These 
results demonstrate that in general HIV-1 infected individuals have high serum IP-10 
levels and that despite effective antiretroviral therapy serum levels of IP-10 remain 
elevated (figure 4.3).  
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Table 4.1. Luminex Assay-Cytokine and Chemokine profiles of the study participants 
compared to the profiles of healthy HIV-negative controls. 
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Figure 4.3. IP-10 serum levels isolated from HIV-1 sero-positive, HIV-1 
sero-positive on ART, or sero-negative subjects were measured using a 
standard multi-plex Luminex assay. Graphs represent mean and standard 
deviations (*represents p<0.05; n=13, n=15 and n=10 respectively; 
p<0.0001; 796.8±472.4pg/ml vs. 342.2 pg/ml±88.17pg/ml vs. 222.4 
pg/ml±62.22 pg/ml). A Kruskal-Wallis test followed by Dunn’s multiple 
comparison test was used. 
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iii. Impact of high IP-10 levels on IFN-! Production 
 Firstly, we wanted to investigate what effect high levels of IP-10 have on 
lymphocytes. So we examined the impact of exposure to high IP-10 levels (500, 10,000, 
100,000 pg/mL) for 24 hours on PBMCs from healthy HIV-1 negative subjects followed 
by antigen stimulation with CEF (CMV, EBV, Flu) peptides or influenza proteins. Our 
findings show that exposure to high levels of IP-10 for 24 hours led to a significant 
decrease in IFN-! production after antigen stimulation for both CEF and influenza 
antigens. Specifically, we observed using a standard ELISpot assay the number of cells 
capable of secreting IFN-! after treatment with our observed physiological high IP-10 
levels (500pg/ml) decreased from an average of 335.6 ± 336.1 to 70.6 ± 71.9 SFC/106 
PBMCs for CEF (figure 4.4A; p=0.00057) and 977.1 ± 926.5 to 542.9 ± 690.2 SFC/106 
PBMCs for influenza proteins (figure 4.4B; p=0.0115).  
 Observing the effect of high levels of IP-10 on IFN-! production on PBMCs from 
healthy uninfected individuals then led us to examine the impact of high IP-10 levels on 
PBMCs from HIV-1 infected subjects on stable ART. We found that treatment with IP-10 
(500pg/ml) for 24 hours resulted in a significant decrease in the ability of PBMCs from 
HIV-1 infected subjects on ART to produce IFN-! in response to CEF peptides (figure 
4.4C; 3088 ± 232.8 vs. 2329 ± 173.6 SFC/106 PBMCs; p=0.0027), influenza proteins 
(figure 4.4D; 211.3 ± 34.2 vs. 0.417 ± 0.83 SFC/106 PBMCs; p=0.0011), and HIV-1 
consensus sequence subtype B gag peptides (figure 4.4E; 510.3 ± 110.1 vs. 145.4 ± 
7.6 SFC/106 PBMCs; p=0.0071).  
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Figure 4.4. PBMCs from HIV-1 sero-negative individuals and HIV-1 infected 
subjects on ART were exposed to IP-10 for 24 hours.  Subsequently, the cells 
were stimulated with viral antigens.  The number of cells capable of secreting 
IFN-! was decreased when stimulated with A) CEF peptides (n=6; p=0.00057) 
or B) Flu proteins (n=4; p=0.0115); * represents p<0.05. The number of cells 
capable of secreting IFN-! was decreased in HIV-1 infected subjects on ART 
when stimulated with C) CEF peptides (n=4; p=0.0027); D) flu proteins (n=4; 
p=0.0011) and E) gag peptides (n=4; p=0.0211). Graphs represent average 
IFN-! production and standard deviations. CEF: is a combination of CMV, 
EBV, Flu peptides. 
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iv. Impact of high IP-10 levels on T-cell function 
 We demonstrated that exposure to high levels of IP-10 could dampen the 
production of IFN-! by PBMCs. We next wanted to examine whether high levels of IP-10 
impacted the production of other cytokines and chemokines in HIV-1 infected subjects 
on ART using a Luminex assay. Specifically, we found after CD3 stimulation that the 
secretion of IL-10 (p=0.0177), GM-CSF (p=0.0012), TNF-" (p=0.0006), IFN-"2 
(p=0.002), IL-12p70 (p=0.0009), and IL-13 (p=0.007) decreased significantly with IP-10 
treatment (500pg/ml) for 24 hours (figure 4.5).  
Additionally, Bett’s et al.49 demonstrated that HIV-1 non-progressors maintain 
highly functional CD8+ T-cells compared to progressors. And while the Luminex assay 
allows us to examine multiple secreted targets, flow cytometry allows us to examine 
what specific cells are producing those secreted targets. We therefore examined the 
ability of T-cells from HIV-1 infected subjects on ART to produce IL-2, MIP-1#, and TNF-
" after treatment with high levels of IP-10 (500pg/mL) followed by CD3 stimulation. We 
found that treatment with IP-10 for 24 hours led to no significant impact on the 
expression of IL-2 by both CD4+ (figure 4.6A,B; p=0.813) and CD8+ T-cells (figure 
4.6C,D; p=0.578). Similarly we found no impact of IP-10 on the expression of MIP-1# in 
CD4+ (figure 4.6A,B; p=0.0625) and CD8+ T-cells (figure 4.6C,D; p=0.5). However, we 
did observe that treatment with IP-10 affected the expression of TNF-" in CD4+ (figure 
4.6A,B; p=0.0075) and CD8+ T-cells (figure 4.6C,D; p=0.0075). Of note, in regards to 
TNF-", we see no impact of IP-10 when PBMCs are stimulated with gag peptides via 
Luminex (p=0.124) or flow cytometry (CD4: p=0.182, CD8: p=0.182), suggesting that IP-
10 may have a stronger impact on certain immunological markers depending on the type 
of stimulation. 
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Even more, Migueles et al.45 demonstrated the potential importance of 
proliferative capacity in HIV-1 non-progressors. We examined the effect of treatment 
with IP-10 for 24 hours on the ability of T-cells from HIV-1 infected subjects on ART to 
proliferate in response to antigen stimulation for 5 days using a standard CFSE assay.  
We found that treatment with IP-10 (500pg/ml) led to a trending decrease in the 
proliferative capacity of T-cells in response to stimulation with CEF peptides (figure 
4.7A,B; p=0.0625), influenza proteins (figure 4.7A,B; p=0.0313), and gag peptide 
stimulation (figure 4.7A,B; p=0.0625).  
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Figure 4.5. Secretion of cytokines and growth factors as measured by a standard 
Luminex assay. Graphs show the secreted levels of IFN-!, IL-10, GM-CSF, TNF-", IFN-
"2, IL-12p70, and IL-13 in supernatants after treatment with media alone, IP-10 
(500pg/ml), or Anti-IP-10 (1µg/ml) in response to 24 hour stimulation of PBMCs from HIV-
1 infected subjects on ART with CD3/CD28/CD49d antibodies. Graphs depict mean and 
standard deviation. * represents p<0.05. A friedman test followed by Dunn’s multiple 
comparison test was used. 
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Figure 4.6 
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Figure 4.6. Expression of IL-2, MIP-1# and TNF-" after treatment with media alone, 
IP-10 (500pg/ml), or Anti-IP-10 (1µg/ml) in response to stimulation with 
CD3/CD28/CD49d antibodies in A, B) CD4+ T-cells and C, D) CD8+ T-cells from HIV-
1 infected subjects on ART as measured by multi-parameter flow cytometry. Graphs in 
B and D represent mean and standard deviation. A Friedman test followed by Dunn’s 
multiple comparison test was used. 
 
92  
Figure 4.7. A) Example of PBMCs from an HIV-1 infected subject on ART treated with media alone, 
500pg/ml of IP-10, or 1µg/ml of anti-IP-10 NAb for 24 hours. Following this, cells were incubated with 
CFSE (2.5µM) for 5 min at room temperature. Cells were washed and incubated with media alone, CEF 
peptides (0.03µg/ml), Flu proteins (Protein Sciences Corp.: A/Brisbane/59/07, 10ug/ml; 
A/Brisbane/10/07, 10ug/ml; B/Brisbane/60/08, 10ug/ml), gag peptides (2µg/ml) for 5 days at 37°C in 96-
well plates. The mean fluorescence intensity of CFSE was used to determine T-cell proliferative 
responses of each of the treatment conditions (media alone, 1µg/ml anti-IP10) within each of the antigen 
stimulation conditions. B) Comparison of the percentage of cells that are CFSE dim in the treatment 
conditions, * represents p<0.05. Graphs represent mean and standard deviation. 
B 
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v. High levels of IP-10 and Calcium Mobilization 
 Since the IP-10/CXCR3 signaling pathway is involved in calcium mobilization9, 
we examined the impact of high levels of IP-10 on the calcium response using a flow-
based calcium assay. We found that treatment with high levels of IP-10 (500, 
100,000pg/mL) for 24 hours led to a blunting of the calcium response in PBMCs from 
healthy HIV-uninfected controls after stimulation with a standard CD3 agonist (figure 
4.8A,B; p=0.0278). Additionally, we observed that the calcium response was dose 
dependent on the IP-10 dose, with no IP-10 treatment having the highest calcium 
response, followed by the 500pg/mL dose, and then by the 100,000pg/mL dose.  
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Figure 4.8. A) Example time-course Ca2+ responses elicited in healthy HIV-negative 
PBMCs treated with or without IP-10 (500pg/ml or 100,000pg/ml) for 24 hours 
followed with stimulation with a CD3 OKT3 agonist. Graph represents fluorescence 
emission of Fura-2, AM cell permeant over the course of 8 minutes. The first-top 
(Red) line represents no treatment with IP-10, the second (blue) line represents 
treatment with 0.5ng/ml of IP-10 for 24 hours, and the third (green) line represents 
treatment with 100ng/ml of IP-10 for 24 hours. B) Mean fluorescence intensity of Fura-
2, AM in response to treatment with or without IP-10 (500pg/ml or 100,000pg/ml) in 
total PBMCs (n=3; p=0.0278), CD4+ T-cells alone (n=3; 0.0051, or CD8+ T-cells 
alone (n=3; p=0.0278). Graphs represent means and standard deviations. 
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vi. High levels of IP-10 and p38 MAP Kinase phosphorylation 
 We next wanted to determine whether other signaling pathways were affected by 
treatment with high levels of IP-10 (500pg/mL) for 24 hours followed by stimulation with 
CEF peptides or influenza proteins. We found that treatment with IP-10 led to a 
significant decrease in the expression of phosphorylated p38 (Thr180/Tyr182) MAP 
Kinase, a member of the IP-10/CXCR3 signaling pathway, after CEF peptide (figure 
4.9A,B; p=0.021) and influenza protein stimulation (figure 4.9A,B; p=0.021). Secondly, 
we observed that IP-10 treatment followed by CEF peptide (figure 4.9A,B; p=0.021) or 
influenza protein (figure 4.9A,B; p=0.021) stimulation led to a significant increase in the 
expression of STAT-1 (Tyr707) phosphorylation. However, we saw no significant impact 
of IP-10 treatment on the phosphorylation of other phosphorylated proteins, specifically, 
ATF2, ERK, HSP27, JNK, MEK1, MSK1, c-Jun, and p53.  
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Figure 4.9. Phosphorylated protein fold change in expression due to 24 hour treatment with IP-10 
(500pg/ml) followed by CEF or flu protein stimulation respectively. A) CEF stimulated phospho-protein 
expression: STAT-1 (Tyr707; p=0.021), ATF2 (Thr71; p=0.500), ERK (Thr185/Tyr187; p=0.875), HSP27 
(Ser78; p=0.250), JNK (Thr183/Tyr185; p=0.625); MEK1 (Ser222; p=0.250), MSK1 (Ser212; p=0.500), c-
Jun (Ser73; p=0.375), p53 (Ser15; p=0.875), and p38 (Thr180/Tyr182; p=0.021). B) Flu protein 
stimulated phosphor-protein expression: STAT-1 (Tyr707; p=0.021), ATF2 (Thr71; p=0.250), ERK 
(Thr185/Tyr187; p=0.581), HSP27 (Ser78; p=0.625), JNK (Thr183/Tyr185; p=1.00); MEK1 (Ser222; 
p=0.500), MSK1 (Ser212; p=0.750), c-Jun (Ser73; p=0.875), p53 (Ser15; p=0.875), and p38 
(Thr180/Tyr182; p=0.021). Expression levels were determined using a multi-plex Luminex assay. Graphs 
represent means and standard deviations (n=4). 
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vii. Enhancing T-cell responses with an anti-IP-10 Neutralizing Antibody.  
 We next wanted to determine whether we could enhance T-cell responses in 
HIV-1 infected subjects on ART by blocking IP-10 using a neutralizing antibody against 
IP-10. We observed that after antigen stimulation, the secretion of IP-10 increases 
(figure 4.10; p=0.0043) in addition to the already present levels of IP-10, so examining 
the impact of blocking IP-10 was of interest. Therefore, we examined the effect of 
neutralizing IP-10 on the ability of lymphocytes to produce IFN-!, proliferate in response 
to antigen stimulation, and degranulate and produce cytotoxins.  
 When blocking IP-10 using the neutralizing antibody we observed a significant 
increase in the ability of PBMCs to produce IFN-! in response to gag peptide stimulation 
(figure 4.11; p=0.0248). We specifically saw an increase in the production of IFN-! from 
an average of 735.8±1114 to 1268±1607 SFC/106 PBMCs. In addition to IFN-!, when we 
examined by flow cytometry the impact of blocking IP-10 with the neutralizing antibody, 
we found a significant increase in the expression of TNF-" in CD4+ (figure 4.6A,B; 
p=0.0197) and CD8+ T-cells (figure 4.6C,D; p=0.0177) after CD3 stimulation compared 
to IP-10 treatment, while we saw no changes in the expression of IL-2 and MIP-1# by 
CD4+ (figure 4.6A,B; IL-2: p=0.954; MIP-1#: p=0.367) and CD8+ T-cells (figure 4.6C,D; 
IL-2: p=0.522; MIP-1#: p=0.338). Furthermore, when we examined by Luminex the 
impact of blocking IP-10 on the secretion of other immunological markers, we found that 
using the neutralizing IP-10 antibody led to increase in the secretion of IFN-! 
(p=0.0278), IL-10 (p=0.0286), GM-CSF (p=0.0043), TNF-" (p=0.0002), IFN-"2 
(p=0.005), IL-12p70 (p=0.001), and IL-13 (p=0.0023) after CD3 stimulation by PBMCs 
compared to treatment with IP-10 (figure 4.5).  
 Also, we examined the effect of blocking IP-10 on functions suggested to be 
associated with the control of HIV-1 infection, that is the ability for CD8+ T-cells to 
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degranulate and produce cytotoxins, as well as proliferative capacity. Blocking IP-10 led 
to an increased ability for CD8+ T-cells from HIV-1 infected subjects on ART to 
degranulate (express CD107a) and produce perforin and granzyme B in response to gag 
peptide stimulation (figure 4.12; p=0.0009).  
 Similarly, when we examined the impact of using a neutralizing antibody against 
IP-10, we found a significant increase in the ability of lymphocytes to proliferate in 
response to stimulation with CEF peptides (p=0.0078), Flu protein (p=0.0078), and gag 
peptide (p=0.0234) stimulation (figure 4.7A,B).  
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Figure 4.10. Secretion of IP-10 in supernatants after 24 hour stimulation of PBMCs 
from HIV-1 infected subjects on ART with CD3/CD28/CD49d antibodies. Graph 
represents mean and standard deviation (n=4; p=0.0043). 
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Figure 4.11. PBMCs isolated from HIV-1 infected individuals on ART were stimulated 
with HIV-1 gag peptides in the presence of anti-IP-10 neutralizing mAb (1µg/ml). 
Increases were observed in the number of antigen specific cells capable of producing 
IFN-! (n=8; p=0.0248). Graph represents mean. 
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Figure 4.12. PBMCs isolated from HIV-1 sera-positive individuals on ART were 
stimulated with HIV-1 gag in the presence of anti-IP-10 neutralizing mAb. Increases 
were observed in the percentage of cells capable of killing or CD8+ CD107a+ 
Perforin+ Granzyme B+ cells (n=3; p=0.0009). Graphs represent mean and standard 
deviations. A Friedman test followed by Dunn’s multiple comparison test was used. 
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viii. HIV-1 infected individuals and high CD26 levels/expression  
 In order to better understand why IP-10 may be affecting T-cell functionality we 
sought to determine whether processing by CD26 could play a role in IP-10’s observed 
effects. HIV-1 infected subjects on ART had significantly higher serum levels of soluble 
CD26 as compared to healthy HIV-uninfected subjects (figure 4.13; p=0.0084). 
Furthermore, when examining whether IP-10 treatment (500, 100,000pg/ml) had an 
impact on the cell surface expression of CD26, treatment with IP-10 led to an increase in 
the expression of CD26 on CD4+ and CD8+ T-cells from healthy HIV-uninfected 
subjects (figure 4.14; CD4: p=0.012; CD8: p=0.0495) and HIV-1 infected subjects on 
ART (figure 4.14; CD4: p=0.0081; CD8: p=0.0081).  
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Figure 4.13. Absorbance (nm) values via standard ELISA assay measuring serum 
soluble levels of the amino-peptidase CD26 (DPPIV) in HIV-1 infected subjects on 
ART (n=15) and healthy HIV-negative subjects (n=10). Graph represents mean and 
standard deviation. 
Figure 4.14. Surface expression of CD26 (DPPIV) on CD4+ and CD8+ T-cells from 
HIV-uninfected subjects (n=6) and HIV-1 infected subjects on ART (n=6) after 24 
hour treatment with recombinant human IP-10 (0, 500, or 100,000pg/ml). Graphs 
represent average change in mean fluorescence intensity and standard deviation. A 
friedman test was used. 
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ix. Mechanism of Action 
Finally, we wanted to determine whether IP-10 was directly exerting its effects on 
T-cells or indirectly, such as through antigen presenting cells. Using flow cytometry we 
found that IP-10 not only impacted the production of IFN-! by total PBMC CD4+ 
(p=0.0286) and CD8+ T-cells (p=0.0286), but also found that there was reduced IFN-! 
production when treating isolated CD4+ (p=0.0026) and CD8+ (0.0019) T-cells with IP-
10 (500pg/ml) followed by CD3 stimulation (figure 4.15). Similarly, when examining the 
calcium response of isolated T-cell subsets, treatment with IP-10 (500, 100,000pg/ml) 
led to a significant decrease in the calcium response in isolated CD4+ (p=0.0051) and 
CD8+ (p=0.0278) T-cells (figure 4.8B).  
Knowing IP-10 is involved in calcium mobilization through signaling of its 
receptor, CXCR3, we sought to investigate whether IP-10 was exerting its dampening 
effects by blocking CXCR3 signaling. When using an antagonist against CXCR3 there 
was a significant decrease in the production of IFN-! in response to CEF peptide 
(p=0.038) and influenza protein (p=0.0212) stimulation (figure 4.16). Even more, as 
hypothesized, using a CXCR3 antagonist led to a decrease in the calcium response 
(figure 4.16; p=0.0174).  
Thirdly, we examined whether IP-10 could affect the expression of MHC Class I 
and II molecules and thereby potentially disrupt normal TCR signaling. We found that 
treatment with IP-10 (500pg/ml) for 24 hours led to no significant change in the 
expression of HLA Class IA,B,C and HLA-DR on total CD3+ T-cells (HLA-Class I: 
p=0.875; HLA-DR: p=0.125), CD4+ (HLA-Class I: p=0.875; HLA-DR: p=0.875),  and 
CD8+ T-cells (HLA-Class I: p=1.0; HLA-DR: p=0.375), and CD3-CD68+CD33+ 
macrophage (HLA-Class I: p=0.625; HLA-DR: p=0.625) subsets (figure 4.17). Likewise, 
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it is shown that expression of inhibitory receptors, such as programmed death-1 (PD-1), 
is associated with blunted T-cell function in those infected with HIV-1234. However, we 
found no change in the expression of PD-1 on CD4+ (p=0.367) and CD8+ (p=0.553) T-
cells after treatment with IP-10. Additionally, we saw no effect of blocking IP-10 on the 
expression of PD-1 (figure 4.18). Thereby suggesting other mechanisms of action for 
IP-10. 
Therefore, we hypothesized that IP-10 may be processed by CD26 to its short 
form and in turn function as an antagonist. So we examined whether using a CD26 
inhibitor would lead to improvement in T-cell function in HIV-1 infected subjects on ART. 
Using a CD26 inhibitor led to an increase in IFN-! production in response to CEF 
peptide (p=0.0146), influenza protein (p=0.0387), and gag peptide (p=0.0392) 
stimulation (figure 4.19A). Furthermore, we saw an increase in the calcium response 
(figure 4.19B; p=0.0196). Finally, when we examined the levels of the IP-10 isorforms, 
HIV-1 infected subjects on ART had Total IP-10 levels at 1062±637.0 pg/ml, IP-10 Long 
levels at 1330±22.4pg/ml, IP-10 short form levels at 464.8±48.8 pg/ml (figure 4.20). 
When we examined the levels of IP-10 short form relative to Total IP-10 levels we saw 
that the levels were highest in untreated HIV-1 infected individuals (p=0.002), followed 
by HIV-1 infected subjects on ART (p=0.064), and then by HIV-negative individuals 
(figure 4.20). 
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Figure 4.15. PBMCs, CD4+ and CD8+ were obtained from HIV-1 sero-negative 
individuals. Cells were treated with 500pg/ml IP-10 or not (media alone). Cells were then 
stimulated with anti-CD3 and costimulatory CD28 and CD49d antibodies and assessed for 
IFN-! production. Data is presented for Gating strategy and IFN-! expression in Total 
PBMC-CD4+ T-cells (n=4, p=0.0286); Total PBMC-CD8+ T-cells (n=4; p=0.0286); isolated 
CD4+ T-cells (n=4; p=0.0026); and isolated CD8+ T-cells (n=4; p=0.0019) as measured 
by multi-parameter flow cytometry. Graphs represent means and standard deviations. 
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Figure 4.16. PBMCs from healthy HIV-negative subjects were treated with 500pg/ml 
of a CXCR3 antagonist for 24 hours. This treatment led to a decrease in IFN-! 
production in response to CEF (n=5; p=0.0380) and flu protein (n=5; p=0.0212) 
antigen stimulation and the calcium response (n=4; p=0.0174). Graphs represent 
mean and standard deviation. 
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HLA-Class I (A, B, C) 
HLA-DR 
Figure 4.17. HLA-Class I (HLA-A, -B,-C) mean fluorescence intensity in media alone and IP-10 
(500pg/ml) treated PBMCs. CD3+ T-cells (p=0.875); CD3+CD4+ T-cells (p=0.875); CD3+CD8+ 
T-cells (p=1.0); CD3-CD68+CD33+ Macrophages (0.625). HLA-DR mean fluorescence intensity 
in media alone and IP-10 (500pg/ml) treated PBMCs. CD3+ T-cells (p=0.125); CD3+CD4+ T-
cells (p=0.875); CD3+CD8+ T-cells (p=0.375); CD3-CD68+CD33+ Macrophages (0.625). 
Graphs represent mean and standard deviation. 
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Figure 4.18. PD-1 expression on CD4+ (p=0.367) and CD8+ (p=0.553) T-cells from 
HIV-1 infected subjects on ART after 24 hour treatment with media alone, IP-10 
(500pg/ml), or Anti-IP-10 (1µg/ml) followed by stimulation with CD3 and CD28/CD49d 
co-stimulatory antibodies. Graphs represent mean fluorescence intensity and 
standard deviation. A Friedman test followed by Dunn’s multiple comparison test was 
used. 
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Figure 4.19. PBMCs from HIV-1 infected subjects on ART were treated with 
500pg/ml of a CD26 inhibitor for 24 hours. This treatment led to a increase in A) IFN-
! production in response to CEF (n=4; p=0.0146) and flu protein (n=4; p=0.0387) and 
gag (n=4; p=0.0392) antigen stimulation and B) the calcium response. (left panel 
example of histogram illustrating Fura-2, AM mean fluorescence intensity of PBMCs 
treated with media alone (Red) and CD26 inhibitor [blue]). Right panel compiled 
calcium responses (n=4; p=0.0196). Graphs represent mean and standard deviation. 
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Figure 4.20. Left panel: Plasma levels of Total IP-10 (1062±637.0pg/ml), Long form 
of IP-10 (1330±22.4pg/ml), and short form of IP-10 (464.8±48.8pg/ml) in HIV-1 
infected subjects on stable ART. Right Panel: Plasma IP-10 short form (pg/ml) 
relative to total in healthy HIV-negative subjects, HIV-1 infected subjects on stable 
ART, and untreated HIV-1 infected. A one-way ANOVA followed by bonferroni’s 
multiple comparison test was used.  !
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4.4 Discussion 
 i. IP-10 and T-cell Function 
As previously discussed we found that IP-10/CXCL10 was elevated in the sera of 
HIV-1 infected subjects on ART compared to healthy controls. Additionally, while the 
serum levels of IP-10 are highest in untreated HIV-1 infected subjects, even with ART, 
the levels remain elevated compared to healthy uninfected individuals. In this chapter we 
investigated the impact that these elevated serum levels of the pro-inflammatory 
chemokine, IP-10, have on HIV-1 infected subjects on stable antiretroviral therapy. The 
data presented here demonstrates that at elevated levels, IP-10 can blunt T-cell 
function. Firstly, we found that exposure to elevated IP-10 led to a decrease in the ability 
of PBMCs from both HIV-uninfected subjects and HIV-1 infected subjects on ART to 
produce IFN-! in response to stimulation with recall antigens. In other words, these 
findings suggest the potential impact elevated IP-10 may have on the ability of these 
individuals to respond to vaccines. Even more, IP-10’s role in other co-
morbidities/opportunistic infections, such as type 1 diabetes and hepatitis C virus 
infection130, 155, that also affect those infected with HIV-1, marks it as a potential 
therapeutic target.  
 In addition to the observed impact of IP-10 on IFN-! production, we found that IP-
10 can also affect the ability of lymphocytes to produce TNF-", IL-10, somewhat GM-
CSF, while we observed no significant effect on the production of other cytokines 
previously shown to be part of the polyfunctional antiviral response, specifically, IL-2 and 
MIP-1#. Importantly, we also observed that treatment with IP-10 led to a stunting of the 
proliferative capacity of lymphocytes from HIV-1 infected subjects on ART in response to 
stimulation with recall antigens. While definitive correlates of protection are yet to be 
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established for control of HIV-1 infection, several functions, which include production of 
IL-2, MIP-1#, IFN-!, TNF-", degranulation and production of cytotoxins, and proliferative 
capacity are suggested to correlate with better control of HIV-1 infection. Likewise, these 
functions are more prominent in HIV-1 infected non-progressors40, 45, 49, 53. Similarly, 
polyfunctional CD8+ T-cells responses are also seen during other infections, which 
include influenza, CMV, and EBV235, 236. Hence, if elevated levels of IP-10 lead to 
blunting of these functions, that in turn could impact the ability of ART-treated individuals 
to elicit protective responses against non-HIV infections.  
 Elevated serum levels of IP-10 are also associated with more rapid disease 
progression and HIV-1 viral replication12, 134. Conversely, reduced levels of IP-10 are 
suggested to be protective from acquisition of HIV-1 infection138. As shown in this 
chapter, if elevated levels of IP-10 lead to blunting of important T-cell functions, blocking 
IP-10 should lead to enhancement of T-cell function. Moreover, we show that not only do 
HIV-1 infected subjects on ART have elevated serum IP-10 levels, but upon antigen 
stimulation the levels of IP-10 increase significantly, potentially exacerbating the 
observed issues further. Indeed, when we block IP-10 using a neutralizing antibody we 
observe significant improvements in the production of IFN-!, IL-10, GM-CSF, TNF-", IL-
12p70, IFN-"2, and IL-13. Of these cytokines IFN-!, TNF-", IL-12p70, and IFN-"2 are 
involved in IP-10 signaling9, so at high levels, IP-10 may serve to regulate its inducers. 
Studies in mice, show that mice deficient in IP-10, but not MIG, have an increase in 
effector cells capable of producing IFN-!237. As well, Bromley et al.127 show that signals 
provided by IP-10 may dominate signals from the TCR. Thus, blocking IP-10 may 
improve T-cell functionality. Further, when examining functions shown to be important in 
viral control in HIV non-progressors, we see that blocking IP-10 leads to an 
enhancement in the ability of lymphocytes from HIV-1 infected subjects on ART to 
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proliferate in response to recall antigens. However, due to the antigens used in this 
study, specifically Flu proteins and CEF peptides, could suggest effects of IP-10 on other 
PBMC subsets, such as antigen-presenting cells since Flu protein has the potential to 
signal to dendritic cells directly through toll-like receptor stimulation for example. On the 
other hand CEF peptides could support a direct effect on T-cells due to their mechanism 
of presentation and signaling. Also, we demonstrate that using a neutralizing antibody 
against IP-10 can enhance the ability of CD8+ T-cells from HIV-1 infected subjects on 
ART to degranulate and produce perforin and granzyme B. These results suggest an 
enhancement in the ability of T-cells to potentially better control HIV-1 infection.  
 
 ii. Proposed model of action of elevated IP-10 levels 
 The results presented in this chapter also led us to propose a potential model for 
a mechanism of action for elevated serum levels of IP-10. First, we investigated whether 
IP-10 was acting by exerting its effects directly or indirectly on T-cells. We found that 
exposure to elevated levels of IP-10 could directly impact IFN-! in CD4+ and CD8+ T-
cells. Interestingly, we did not see an effect of IP-10 on the CCR5 ligand MIP-1#. 
Previous virological studies in mice suggest that since CXCR3 tends to be expressed on 
similar cells as CCR5, when one of the receptors is knocked out, infection is not as 
severe as knocking both out. These findings would suggest a potential redundant role of 
dual CXCR3/CCR5 expression on T-cells, and thus suggesting a potential reason for the 
lack of an effect of IP-10238. Second, one of IP-10’s functions is in the regulation of 
calcium mobilization9, 122. Accordingly, we examined the impact of elevated levels of IP-
10 on the calcium response and found that IP-10 blunted the calcium response. It is 
possible that constant signaling by IP-10 due to its elevation could lead to depletion of 
calcium reservoirs. Contrarily, previous researchers have demonstrated that IP-10 when 
in its antagonistic form can blunt the calcium response; we then sought to examine this 
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further. Doing this, we found again that IP-10 blunted the calcium response of CD4+ and 
CD8+ T-cells directly. Additionally, these findings point out that high levels of IP-10 affect 
the calcium responses after CD3 crosslinking. This could be due to the synergistic 
signaling between CXCR3 and CD3242. Third, we explored potential intracellular 
signaling proteins involved in IP-10/CXCR3 signaling. We specifically found a significant 
decrease in the phosphorylation of the p38 MAP kinase. Gratton et al.239 illustrate that in 
order to potentially avoid damage from multiple inflammatory signals, p38 can be down-
regulated in order to ensure cyto-protection. Thus, it is possible that at elevated levels 
IP-10 binding to CXCR3 helps to throttle back the T-cell response upon activation with 
antigen. Also, as is shown, STAT-1 phosphorylation on tyrosine-707 is increased, but 
down-regulation of the calcium and p38 signals could impact whether STAT-1 is 
phosphorylated on its serine-727 site, important for its function and can thereby possibly 
contribute to the observed dampening of T-cell function240, 241. However, further research 
is needed to understand the mechanisms of IP-10 on these pathways. Fourth, we 
explored whether at elevated levels, IP-10 was leading to cell death. We found that 
treatment of PBMCs from both HIV-uninfected and HIV-1 infected individuals on ART 
with IP-10 did not affect cell viability, suggesting that other potential mechanisms may 
explain IP-10’s role in T-cell function. It is possible that IP-10 could affect the expression 
of MHC complex molecules, which would affect normal TCR signaling. Furthermore, 
down-regulation of MHC Class molecules could leave cells vulnerable to NK cell 
targeting242. However, exposure to elevated levels of IP-10 did not affect the expression 
of HLA Class-I (A, B, and C) and HLA-DR on T-cells or macrophages. Similarly, 
expression of PD-1 on T-cells, is associated with blunted function in those infected with 
HIV-1234. Nevertheless, we found no change in the expression of PD-1 on CD4+ and 
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CD8+ T-cells after treatment with IP-10. And we saw no effect of blocking IP-10 on the 
expression of PD-1. These findings suggest alternative mechanisms for IP-10’s effects.   
 Research by others shows that high levels of IP-10 correlate with non-
responsiveness to HCV therapy and suggest a potential mechanism of action130. These 
researchers found that IP-10 is cleaved by the amino-peptidase CD26 (DPPIV) to a 
short antagonistic form. This antagonistic form can still bind CXCR3, but acts as a 
competitive antagonist128. Our findings suggest that similar to HCV infection, the 
elevated IP-10 observed in HIV-1 infected subjects on ART may be processed to its 
short form and in turn block normal signaling via CXCR3. In fact, we found that using an 
antagonist against CXCR3 led to similar results as the elevated levels of IP-10, that is, 
we observed a decrease in IFN-! production and a blunted calcium response. 
Additionally, blunted signaling via CXCR3 could reduce the synergistic effect between 
CXCR3 and CD3& signaling243. This could therefore lead to a reduction in T-cell 
functions such as IFN-! production and reduction in phosphorylation of p38. Moreover, 
we examined the serum soluble and surface expression levels of CD26. We 
demonstrate that HIV-1 infected subjects on ART have higher serum soluble CD26 
compared to healthy HIV-uninfected controls. Similarly, we observed that exposure to 
elevated levels of IP-10 led to an increase in the surface expression of CD26 on CD4+ 
and CD8+ T-cells. Even more, when we used an inhibitor of CD26, we found an 
improvement in the ability of HIV-1 infected subjects on ART to produce IFN-! and elicit 
a calcium flux response.  Finally, when we examined the short form of IP-10, we found 
that relative to total IP-10 levels, untreated HIV-infected subjects had the highest, 
followed by HIV-1 infected subjects on ART, and then by healthy HIV-negative subjects, 
suggesting a potential role for IP-10 short in HIV-1 infection.  
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 With these findings we propose a potential model for IP-10’s impact on T-cell 
function in HIV-1 infected individuals on ART. We propose that at elevated levels, IP-10 
is in an environment that has high levels of CD26. By the same token, upon cell 
activation, either through infection or vaccination, the surface expression of CD26 on 
cells can potentially increase as well as the production of IP-10. In this environment it is 
possible that IP-10 can come in contact with CD26 and be processed to its short form. 
As a way to potentially reduce unnecessary damage from multiple inflammatory signals, 
the short form of IP-10 provides antagonistic signals that help dampen pathways and 
functions that can possibly contribute to more immune activation and eventual T-cell 
turnover. Indeed, it is shown that excessive calcium release can lead to apoptosis244. 
Therefore the short form of IP-10 can stunt the calcium response to avoid apoptosis of 
T-cells. As well, its been shown that while the antagonistic form of IP-10 reduces calcium 
signaling and chemotaxis, IP-10’s angiostatic functions are maintained245. This would 
allow for IP-10 to limit further recruitment of activated cells and in turn control excessive 
inflammation to avoid further damage. However, in the context of trying to elicit 
protective T-cell responses with vaccines, IP-10 short’s “protective” role could lead to 
reduced responsiveness to vaccines. In regards to this, it may be necessary to target IP-
10 or its antagonistic form in order to enhance vaccine responses in HIV-1 infected 
subjects on antiretroviral therapy.  
!
Limitations of Study 
 While the findings presented in this study elucidate a potential role for IP-10 in 
affecting T-cell function in HIV-1 infected individuals further investigation is necessary to 
better understand IP-10’s mechanism of regulation. In this study we touch upon potential 
CXCR3 signaling pathways that could be affected by elevated levels of IP-10. However, 
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in addition to further investigating signaling pathways affected, such as NFAT and other 
STAT pathway members, the luminex assay in this study is limited in detecting 
phosphorylation of STAT-1 at both its tyrosine as well as serine site. Investigating how 
STAT-1 is affected could help unravel more intracellular mechanisms involved in IP-10 
regulation. Similarly, further studies are necessary to understand the effect seen on p38 
and its pathway members to see if downregularion is seen in other instances. 
Furthermore, CXCR3 is expressed primarily on activated and memory T-cells, thereby it 
may be necessary to investigate whther high levels of IP-10 can impact normal memory 
responses and differentiation. As well, this study would further benefit from examining 
CD26 activity during the presence of high levels of IP-10. In regards to the isoforms of 
IP-10, the 3-plex luminex assay is limited in its ability to account for all total IP-10 levels. 
This could be due to the need for better capture antibodies, as well as the fact that IP-10 
is processed by other aminopeptidases thereby underestimating the levels of total IP-
10130. Finally, this study is limited in the inaccessibility to obtain the antagonistic form of 
IP-10 to use in directly investigating its role in T-cell function. 
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CHAPTER 5:  
Discussion 
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5.1 Significance 
Developing an effective prophylactic or therapeutic vaccine against HIV-1 
remains an important task in which traditional vaccine approaches have failed. Even 
more vaccine trials, such as Merck’s STEP trial246, led to disappointing results for the T-
cell based vaccine field. Nonetheless, research involving HIV-1 non-progressors and 
non-pathogenic SIV studies continues to reveal insights into the pathogenesis of HIV-1 
infection and potential immune correlates of protection247. Additionally, successes in 
trials like the RV144 trial have shown the potential of eliciting humoral immunity with 
some efficacy248. However, the field of HIV-1 vaccines continues to be a swinging 
pendulum between T-cell based vaccines and antibody-based vaccines. Rather, these 
studies demonstrate how crucial it is to understand the role that both arms of the 
immune system play and it will probably be necessary to elicit both in order to develop 
and effective vaccine or therapy. 
In addition, while HIV-1 infection remains a major cause of morbidity and 
mortality worldwide, the tremendous progress in the development of antiviral regimens 
has helped turn HIV-1 infection from a death sentence to a manageable chronic disease. 
Yet even with these improvements the HIV-1 viral reservoir still poses a barrier to a cure 
for HIV-1 infection and the immune systems of these infected individuals continue to 
deteriorate with age as a result of the damage from HIV-1 infection itself10, 205. The 
studies presented in this thesis examine the ability of individuals on stable antiretroviral 
therapy to respond to a therapeutic vaccine against HIV-1 as well as investigate 
potential alternative therapeutic targets or factors that affect the ability of these 
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individuals to respond to vaccination, one such target being the pro-inflammatory 
chemokine IP-10. 
 
 
5.2 Therapeutic HIV-1 Vaccine 
 With traditional vaccine strategies against HIV-1, the results are troubled with 
safety (e.g. live vaccines) and efficacy issues. However, the field of DNA vaccines has 
overcome early setbacks of low immunogenicity. As well, DNA vaccines offer a safer 
strategy to target pathogens for which a vaccine remains elusive. The question also 
arises whether a vaccine that is effective in a prophylactic setting is effective in those 
already infected with the virus as a therapeutic vaccine and vice versa. Specifically, 
unless an HIV-negative individual is already affected with a chronic illness, their immune 
systems should be apt to respond properly to an effective prophylactic vaccine. On the 
other hand, even for those on ART, the damage that HIV-1 infection14 has caused in 
some if not all these individuals, can blunt their ability to respond to vaccination. Even 
more, while the RV144 trial showed us the possible need for broadly neutralizing 
antibodies, the success was not substantial249. Therefore, as Walker et al.168 suggest it is 
likely that a vaccine strategy that in parallel elicits both a strong T-cell response as well 
as broadly neutralizing antibodies may be the best bet for preventing or treating those 
individuals already infected.  
 In the study in chapter 2, we demonstrated that all individuals in the study 
responded to at least 1 vaccine antigen. In particular, we found that almost all of the 
subjects showed positive responses to pol antigen, and more than half demonstrated a 
positive response to gag. However, half of the individuals did not respond to one of the 
antigens, env, and only 4 of the subjects responded to all three. So in moving forward 
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with this vaccine, boosting the immunogenicity and breadth of the vaccine antigens 
could help to elicit antibody responses as well as stronger CD8+ CTL responses in more 
subjects. Alternatively, this vaccine trial used the same vaccine for the priming and 
boosting strategies. It is possible that combining this vaccine in a different prime-boost 
strategy, such as with a viral vector based strategy could enhance responses171. 
Additionally, while examining peripheral immune responses to vaccines against HIV-1 is 
a good indication of a systemic response, the virus is shown to predominantly affect the 
mucosa of individuals before it disseminates to other tissues5. Therefore researchers 
may be under- or over-estimating the impact of their vaccine regimens. It is thus 
necessary to develop minimally invasive methods of examining these mucosal 
responses as well in order to move the field forward. 
Nevertheless, the vaccine in this study demonstrates firstly, that a DNA-based 
vaccine can elicit potent cellular responses in HIV-1 infected individuals on stable ART 
against HIV-1 antigens. Secondly, this trial demonstrates that cellular responses elicited 
by this vaccine were responses shown to be potential correlates of control of HIV-1 
infection in elite controllers, specifically, CD8+ CTL responses. However, in order to 
examine the potential for control of HIV-1 infection, it is necessary to examine a more 
direct assay of killing that would investigate if the ability to identify and kill virally infected 
cells is enhanced. As well, not all subjects demonstrated potent CD8+ CTL responses, 
thus it is necessary to understand how to better elicit these responses if they are in fact 
important for the control of HIV-1 infection.  
 Further, we identified pre-vaccination baseline cytokine and chemokine profiles 
of these individuals. These results demonstrate potential cytokine or chemokine targets 
that could aid in improving similar vaccine strategies.  
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5.3 Sero-protection to Influenza in HIV-1 infected individuals 
The 2009 H1N1 pandemic demonstrated that being unprepared for such a 
severe risk could possibly leave many individuals unprotected and in danger. With an 
already present risk of influenza in the immune-compromised, including those infected 
with HIV180, 189, lack of preparation for such an outbreak may lead to a wasting of vaccine 
doses, leaving those infected with HIV unprotected still. Specifically, Tebas et al.203 
demonstrated that despite being well controlled on ART, 39% of vaccinated individuals 
do not achieve sero-protection against pandemic H1N1 infection. Likewise, due to lack 
of sero-protection, other studies discuss the need for administration of higher or multiple 
doses of influenza vaccines in order to improve rates of sero-protection in HIV-1 infected 
individuals66, 200. On the same note, a follow-up study comparing the administration of a 
higher than standard dose of the seasonal influenza vaccine, showed that immunizing 
HIV-1 infected subjects with a higher dose of the vaccine improved sero-protection 
rates198. Importantly, our study explored baseline factors that are associated with sero-
protection after vaccination with a standard 15µg dose of the H1N1 vaccine (Novartis).  
Since levels of T-cell immune activation are shown to be associated with HIV-1 
disease progression216 we expected that baseline levels of T-cell activation would be 
associated with responsiveness to H1N1 vaccination. However, this was not the case, 
and instead found a relationship between the baseline frequency of naïve T-cell subsets 
with responsiveness. It is possible that while the levels of immune activation are not 
directly associated with sero-protection, the damage caused by residual immune 
activation can contribute to the turnover and erosion of the naïve T-cell subsets, and 
thus responsiveness to vaccination. Even more, the association between 
responsiveness and naïve T-cell subsets may be indicative that the de novo flu response 
may be affected. Additionally, our analysis of baseline cytokine and chemokine profiles 
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exhibited differences in cytokines between Responders and Non-responders, specifically 
differences in IL-10 and IL-6. Changes in cytokine secretion between Responders and 
Non-responders can therein affect the type and immunogenicity of the response and 
ultimately sero-protection. Furthermore, overall cytokine and chemokine dysregulation 
present in HIV-1 infected individuals on ART can potentially affect responsiveness and 
T-cell function.  
Nonetheless the findings in our study bring up two potential concerns for those 
infected with HIV. Firstly, the population of well-controlled HIV-1 infected individuals is 
living longer and aside from the co-morbidities that are seen to arise in these individuals, 
age itself is further contributing to dysregulation of the immune system and depletion of 
naïve cell subsets. Regarding age as a potential confounding factor should inform 
researchers and clinicians as to investigating better vaccine design and/or dosing for 
those infected with HIV, especially in the event of a future unforeseen pandemic. 
Understanding how to better protect these individuals can ensure that limited vaccine 
doses are administered properly so as to ensure higher rates of sero-protection.  
Secondly, the damage caused by untreated HIV-1 infection can potentially contribute to 
immune reconstitution issues after the initiation or antiretroviral therapy. As ART 
regimens have seen significant improvement and enhanced adherence, issues remain 
with accessibility to therapy and potential side-effects, nonetheless, the obtained 
benefits are undeniably welcomed. Therefore, recent research has sought to determine 
the best timing for the initiation of therapy. If initiating ART at earlier stages of infection 
can lead to better preservation of cell subsets250 important in responses to vaccines, 
then in the case of our study, early ART initiation could better preserve the naïve T-cell 
subset and improve sero-protection rates. However, for those already being treated for 
ART it may be necessary to investigate alternate strategies to improve sero-protection 
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rates. Aside from possible benefits to immune reconstitution, studies examining early 
initiation of ART in those infected with HIV have also seen reduced rates of transmission 
in sero-discordant couples18.  
 
5.4 IP-10 as an immune-therapy target 
IP-10, is a chemokine that can be beneficial or detrimental depending on the 
disease, pathogen, and whether the disease is chronic or acute. Basic research on the 
CXCR3 family of ligands has elucidated the inter-related roles of IP-10, MIG, and I-TAC 
and demonstrates that their functions can be independent of each other, redundant, and 
in some cases antagonistic120. Yet, in regards to IP-10, recent research has opened a 
new door that demonstrates the complexity of this 10kDa chemokine. As the name 
chemokine implies, IP-10 plays an important role in the trafficking of a wide variety of cell 
types9. Knowing this role, it would be expected that a potent chemokine would be 
associated with better immune responses, as it would help immune cells traffic to the 
site of infection. Contrarily, as is the case, excessive recruitment of immune cells can 
lead to increases in inflammation, which if left uncontrolled can become pathogenic. For 
example elevated levels of IP-10 contribute to chronic inflammation observed in 
ulcerative colitis251, in the spinal cord148, and arthritis252.  
Sadly, a chemokine, like IP-10 that is beneficial for diseases like breast 
cancer160, has become an ominous sign of sorts in regards to HCV and HIV-1 infection. 
Recent research by Casrouge et al.130 and others253 has offered insight as to why IP-10 
is associated with inability to respond to HCV therapy and clear infection. These 
researchers demonstrated that IP-10 is processed and truncated (2 amino acid 
truncation) by CD26 to an antagonistic form. These findings have begun to elucidate on 
the paradoxical effects of IP-10. In our study we investigated the role of elevated levels 
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of IP-10 in HIV-1 infected individuals on ART, a novel population in which IP-10’s effects 
is not fully explored. We found that at elevated levels IP-10 could lead to blunting of T-
cell functions, specifically IFN-! production aside from others. Likewise, in HCV infection, 
Riva et al.254 show that in addition to having lower levels of IP-10’s antagonistic form, 
individuals who clear infection have a higher frequency of HCV-specific IFN-! producing 
T-cells. Our findings and those by Riva et al.254 suggest an alternate role for IP-10 in 
potentially regulating inflammation and immune activation. As seen in our study, at 
elevated levels, we see a blunting of the calcium response and down-regulation of p38 
phosphorylation. Reducing such signals, could serve as a possible safety mechanism to 
avoid excessive damage from inflammatory stimuli. However, when trying to elicit a 
response to therapy or a vaccine, blunting T-cell function may lead to the inability to 
achieve adequate immunogenicity. Apart from HCV infection, IP-10’s antagonistic form 
has been implicated in ovarian cancer161. Similarly, reduction of IP-10 has seen benefits 
during influenza infection, and in mouse models236, 255.  
It is therefore necessary to better understand IP-10 in order to develop better 
ways to target this chemokine. The development of anti-IP-10 antibodies to treat colitis 
has seen some success251. By the same token, the use of statins that help target IP-10, 
such as atorvastatin, or indirubin has shown benefits in Chron’s disease and highly 
pathogenic influenza infection, respectively255, 256. Yet, in regards to infections like HCV, 
where the antagonistic form plays a role, research is necessary to understand whether it 
is better to target IP-10 or the antagonist form. Furthermore, as we show in our study, 
HIV-1 infected individuals have elevated CD26 levels. So instead of targeting IP-10 
altogether, it could be beneficial to target CD26, the culprit that processes IP-10. 
However, CD26 is involved in the processing of other chemokines, such as RANTES 
and SDF-1245, so CD26 as a therapeutic target would have to be investigated further. 
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5.5 Future Directions 
In continuing research on the HIV-1 infected population on stable ART there are 
certain questions that can be further investigated. Current studies are investigating the 
potential benefits of initiating ART earlier. As so, it would be interesting to compare 
vaccine responses, to both HIV-1 and non-HIV vaccines, between early and 
late/standard ART initiators. Additionally, understanding the impact of early ART to 
immune reconstitution could provide researchers with a better understanding of potential 
immune correlates for controlling HIV-1. Furthermore, administration of higher doses of 
the influenza vaccine appear to improve sero-protection, but there remains a subset that 
do not achieve protection. Examining the differences in these populations could reveal 
additional factors impacting vaccine responses in HIV-1 infected individuals on ART. 
In regards to the development of a therapeutic HIV-1 vaccine, collaborations 
between research on reservoir eliciting/targeting agents, and the vaccine field could lead 
to a better approach at targeting and eliminating the viral reservoir.  Likewise, 
concerning vaccine development, efforts from the humoral and T-cell based fields should 
be combined so as to better understand the impact of a two-arm vaccine approach. 
Moreover, advances in vaccine technology, particularly DNA vaccines, can aid in 
improving the immunogenicity of vaccine antigens in order to elicit better HIV controlling 
responses.  
On the other hand, basic research that helps researchers understand the impact 
from the dysregulated cytokine and chemokine environment is important. Understanding 
the roles IP-10 can play in the immune response can aid in the creation of immune-
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therapies that help reduce negative effects from this chemokine. However, further 
research regarding IP-10 in the context of HIV-1 infection on ART is still needed. In 
addition to understanding the potential role that IP-10’s antagonistic form may play in 
this patient population, better understanding of IP-10’s receptor, CXCR3, is also 
necessary. CXCR3 itself has 3 isoforms that can have normal or inhibitory functions, so 
exploring their expression and distribution could elucidate on other CXCR3 based 
mechanisms of control120. By the same token, there exist populations of CXCR3 
expressing regulatory T-cells that can traffic in response to IP-10, so it is possible they 
may also play a role in regulating immune responses dependent on IP-10120, 257, 258. Yet, 
we found that high levels of IP-10 affected the secretion of IL-10, an immune-regulatory 
cytokine. It is possible that even if CXCR3+ T-regs are being recruited, their functionality 
too may be affected. Alternatively, IP-10 is shown to have alternate binding sites, such 
as glycosaminoglycans259, which are shown to potentially affect the proliferation of 
epithelial cells. So investigating whether this binding plays a role in T-cell function could 
elucidate on alternate forms of IP-10 regulation. Finally, early studies by Bromley et 
al.127, demonstrate a possible role for IP-10 and the development of the immunological 
synapse during antigen presentation. Understanding whether IP-10 or its antagonist 
form disrupts this interaction could lead to finer targeting of IP-10. In moving forward, our 
lab is looking to the development of an anti-IP-10 agent that could aid in enhancing T-
cell function in those infected with HIV-1 on ART, as well as understanding the role IP-10 
plays in other diseases by using in vivo mouse models.  !
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Materials and Methods 
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6.1 Therapeutic HIV-1 DNA Vaccine Study 
 i. Study Participants 
This study was an open label, Phase I trial conducted at one center in the United 
States (clinicaltrials.gov registration NCT01082692). The study protocol was approved 
by an Institutional Review Board and adhered to the guidelines of Good Clinical Practice 
and the Declaration of Helsinki. Written informed consent was obtained prior to study 
enrollment. Adult HIV-1 infected male and female subjects eligible for participation were 
between 18-55 years of age, currently receiving a highly active antiretroviral therapy 
(HAART) regimen, undetectable plasma viral loads (<75 copies/mL), CD4+ lymphocyte 
counts >400 cells/µL, and nadir CD4+ lymphocyte counts >200 cells/µL. These values 
must have been documented on two separate occasions within 60 days of study 
enrollment. Female subjects of reproductive potential must not have been pregnant or 
nursing and have had a negative serum pregnancy test within 30 days of study entry as 
well as a negative urine pregnancy test on the day of the first immunotherapy dose. 
Major exclusionary criteria included any past or active AIDS-defining illness, malignancy 
requiring chemotherapy, autoimmune disease, or receipt of other immunomodulatory 
therapy within 4 weeks of study entry. 
 
ii. Study Design 
Subjects received a four doses of the PENNVAX®-B (gag, pol, env) 
immunotherapy delivered intramuscularly into the deltoid muscle followed immediately 
by electroporation (EP) with the CELLECTRA® 2000 Adaptive Constant Current device 
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(3 pulses of 52ms duration at 0.5A). Each 0.75 mL dose contained 3 mg of DNA 
encoding Clade B consensus sequence HIV-1 gag, pol, and env expression plasmids in 
equal proportions. Therapeutic immunization followed by EP occurred on Day 0 (1st 
dose), Week 4 (2nd  dose), Week 8 (3rd dose), and Week 16 (4th  dose). Blood collection 
for immunogenicity and virologic assessments was performed during screening, at Day 0 
(prior to dose), and weeks 4 (prior to dose), 8 (prior to dose), 10, 16 (prior to dose), 18, 
24, and 48 (discharge visit). 
 
 iii. Safety Assessment 
Local and systemic injection site reactions, including pain, tenderness, erythema, 
and edema, were assessed within 30 minutes post-dose on the day of each 
immunization as well as 2 weeks later. All local injection site reactions were graded 
according to severity (in accordance with the 2004 AIDS Table for Grading Adult 
Adverse experiences) where grade 1 = mild (minimal pain and/or tenderness, erythema 
or edema < 15cm x 15cm); grade 2 = moderate (notable pain and/or tenderness, 
erythema or edema % 15cm x 15cm); grade 3 = severe (extreme pain and/or tenderness, 
ulceration, superinfection or phlebitis); and grade 4 = potentially life-threatening 
(necrosis of the skin). Adverse events were monitored via telephone follow-ups 24 hours 
after the dose, as well as during in-person visits continuously over the course of the 
study.  
 
 iv. IFN-! ELISpot 
We used ninety-six-well nitrocellulose membrane plates specific for human IFN-
! (MABtech, Nacka, Sweden) to examine IFN-! production by PBMCs. PBMCs were 
either stimulated with media alone, consensus sequence HIV-1 gag, pol, or env 
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peptides. HIV-1 consensus sequence subtype B peptides (2ug/mL) were combined with 
2x105 cells (100ul) per well (triplicate). PBMCs from each time-point (Screening, day 0, 
week 4, 8, 16, 18, 24, and 48) were assessed. PMA/Ionomycin (0.02ug/mL and 2ug/ml 
respectively) was done in triplicate as positive controls. Plates were incubated for 18-24 
hours. Plates were then washed and detector monoclonal antibody was added for 2 
hours followed by washing. Plates then had streptavidin-ALP added for an hour followed 
by washing and finally substrate was added until reaction was stopped and plates were 
washed and dried overnight prior to analysis using ImmunoSpot plate reader. The 
average number of SFC counted in R10 wells was subtracted from the average in 
individual HIV peptide wells and then adjusted to 1 ' 106 PBMCs for each HIV peptide 
pool. Positive Responses were determined using a one-way ANOVA followed by 
Dunnett’s test, comparing each time-point to baseline. 
 
v. Flow Cytometry 
Intracellular cytokine staining was performed as previously described260. We 
measured the potential of cells to express functions shown to lyse HIV-1 infected cells 
by measuring CD8+ CD107a+ Perforin+ Granzyme B+ responses. Antibody fluors are 
as follows: BD Biosciences: CD14, CD16 (PacBlue), IFN-! (FITC), CD3 (APC-Cy7), CD4 
(PerCP-Cy5.5), CD8 (APC), CD45RO (AF700), CD107a (PE-Cy7), Abcam: Perforin (PE; 
clone B-D48), Invitrogen: CD19 (PacBlue), Granzyme B (PETexas-Red), Ebiosciences: 
CD27 (PE-Cy5). Staining for CD107a+ and stimulation (gag, pol, env, SEB) was done as 
previously described260. Cell surface staining was done at 4°C for 30-45min using anti-
CD14, anti-CD16, anti-CD19, anti-CD3, anti-CD4, anti-CD8, anti-CD27, and anti-
CD45RO. Intracellular staining was done following permeabilization at 4°C for 45min-1h 
using anti-perforin, anti-granzyme B, and anti-IFN-!. Subjects’ responses were 
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considered positive if their CD8+ CD107a+ Perforin+ Granzyme B+ responses were 
>0.05% after background subtraction. Gating was done as shown in figure 2.6.  
Prepared cells were acquired using the LSR II flow cytometer equipped with BD 
FACSDiva software (BD Biosciences). Acquired data was analyzed using the FlowJo 
software. 
 
vi. Luminex 
A Luminex cytokine/chemokine assay (Millipore) was used to examine serum 
from 15 HIV-1 infected subjects on ART and 10 healthy HIV-negative controls. The 
assay examined the following serum cytokine/chemokine levels: IL-12p40, IL-12p70, 
IFN-!, TNF-", IL-10, IL-4, IL-5, IL-6, IL-13, IL-2, IL-7, IL-15, G-CSF, GM-CSF, VEFG, 
TGF-", EGF, IP-10, MIP-1", MIP-1#, IL-8, MCP-1, Fractalkine, Eotaxin, IL-17A, IL-1ra, 
IL-1", IL-1#, sCD40L. Cytokine/chemokine profiles were compared between the HIV-1 
infected individuals on ART and the HIV-negative controls using an unpaired t-test. 
 
6.2 Sero-protection after H1N1 Influenza vaccination 
i. Vaccine 
Subjects received a single 15µg dose of the monovalent, unadjuvanted, 
inactivated, split virus H1N1 vaccine (Novartis, Basel, Switzerland). Each participant had 
baseline studies performed at the time of enrollment followed by the intramuscular 
administration of the 2009 H1N1 influenza vaccine (0.5 mL) to one of the deltoid 
muscles, followed by 2 phone calls and serological response evaluations completed 21-
28 days after vaccination. 
ii. Subjects 
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All subjects provided informed consent and the study was approved by the 
University of Pennsylvania institutional review board. HIV-1 infected individuals, older 
than 18 years of age that had an indication to receive the H1N1 vaccine were included in 
the study. Individuals with a known allergy to eggs or other components of the vaccine, a 
history of severe reactions to previous immunization with seasonal flu, known cases of 
H1N1 influenza during the spring of 2009 or previous recipients of the novel H1N1 
vaccine were excluded. Additionally, subjects were excluded if they had received other 
licensed live vaccine within 4 weeks of study entry or inactivated vaccines within 1 week 
of study entry. Other exclusionary criteria included subjects receiving: experimental 
treatments (other than phase III antiretroviral trials), systemic chemotherapy for the past 
36 months, steroids, immunomodulators, or history of Guillain-Barre syndrome. A total of 
120 subjects were included in the study that has been previously presented by Tebas et 
al.203. All patients provided informed consent. Forty-six of the 120 subjects had frozen 
PBMCs available to use for the purpose of this study.  These 46 subjects had baseline 
HAI titers <40, were all on anti-retroviral therapy, their ages ranged from 26-77 with a 
median age of 48, 69.6% were male, 63% were black, 10.9% Hispanic/Latino, 23.9% 
Caucasian, and 2.1% Asian/Pacific Islander. Furthermore, their average CD4+ 
lymphocyte count was 542 cells/µl ± 306.8 cells/µl, average CD4+ lymphocyte nadir of 
193 cells/µl ± 187.2 cells/µl, HIV VL were <400 copies/ml in 90% and 85% below limits 
of quantification. At week 3, 61% of the subjects met the guidelines for protection.  
iii. Hemagglutination inhibition assay 
Antibody titers of the 120 subjects were measured using a hemagglutination 
inhibition assay as previously described214. The hemaglutination assays were done by 
McKittrick et al.198 at Bioqual Inc. For the 46 subjects in this study, if their week 3 titer 
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was greater than 1:40 and had a four-fold increase in their HAI titer, they were classified 
as sero-protected and responders to vaccination, while those with titers less than 1:40 
and/or were less than four-fold increase were classified as non-responders. 
iv. Flow Cytometry 
Samples from 46 of the 120 subjects were available and were examined for their 
memory and activation phenotypes using multi-parameter flow cytometry. Antibody 
fluors are as follows: BD-Pharmigen: CD3 (FITC), CD4 (APC-Cy7), CD8 (AF700), CD27 
(APC), HLA-DR (PE-Cy5); Beckman Coulter: CD45RO (ECD); Ebiosciences: CD38 (PE-
Cy7); Beckton Dickinson: CD25 (PE); BD Horizon: CD127 (V450); Invitrogen: Viability 
Dye (Aqua). 46 subjects were analyzed and cellular (CD27, CD45RO) and activation 
(HLA-DR, CD38) phenotypes were compared using an unpaired t-test between 
responders and non-responders.  Cell surface staining was done at 4°C for 30-45min in 
the dark and gating was done using FlowJo Software as in figure 3.2 after sample 
acquisition on the LSR II running BD FACSDiva software (BD Biosciences). 
v. Predictors of response 
 A multi-variate logistic regression model was used to examine the predictors of 
response, which included viral load, pre-vaccination CD4+ lymphocyte count, CD4+ 
lymphocyte nadir, age, naïve and terminally differentiated CD4+ and CD8+ T-cells. A 
multi-variate logistic regression model was also used to examine the effect of age to 
frequency of CD4+ naïve T-cells and total activated CD4+ T-cells. 
vi. Luminex 
A Luminex cytokine/chemokine assay (Millipore) was used to examine serum 
from the 46 HIV-1 infected subjects on ART and 10 healthy HIV-negative controls. The 
137 
assay examined the following serum cytokine/chemokine levels: EGF, Eotaxin, G-CSF, 
GM-CSF, IFN"2, IFN-!, IL-1", IL-1#, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, 
IL-12p40, IL-12p70, IL-13, IL-15, IL-17A, IP-10, MCP-1, MIP-1", MIP-1#, TNF-", TNF-#, 
and VEGF. Cytokine/chemokine profiles were compared between the HIV-1 infected 
individuals on ART and the HIV-negative controls using an unpaired t-test. 
Cytokine/chemokine profiles were also compared between subjects designated as 
Responders and Non-Responders using and unpaired t-test.  
 
6.3 Impact of IP-10 on T-cell function in HIV-1 infected subjects on ART 
i. Patient Samples 
Sera and PBMCs, isolated CD4+, and CD8+ T-cells from Healthy HIV-negative 
subjects, HIV infected untreated subjects, and HIV-1 infected subjects on ART were 
obtained from the University of Pennsylvania’s Human Immunology Core or the Center 
for AIDS Research. Healthy controls age ranged from 20-55 years of age, with an 
average of 31. HIV-1 infected subjects on ART were well controlled with VL<50 
copies/ml, current CD4 count over 400 cells/µl and CD4 nadir over 200 cells/µl.  HIV-1 
infected subjects median VL was 16511 copies/ml. 
ii. Cell Culture & IP-10 treatment 
Recombinant human IP-10/CXCL10 (Biolegend) treatment doses were 
determined based on the serum levels of IP-10 found in HIV-1 infected subjects on ART 
in our and other studies126134. PBMCs, or isolated CD4+ or CD8+ T-cells were cultured in 
media alone (RPMI 1640 with L-glutamine + 10% FBS and 1% streptomycin/penicillin) or 
media with one of the rhIP-10 doses (500, 10,000, or 100,000pg/ml) for 24 hours. 
Additionally, in the cases indicated below, PBMCs from HIV-negative of HIV-1 infected 
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subjects on ART were treated with 1µg/ml of the anti-IP-10 neutralizing antibody (R&D 
Systems), or 500pg/ml of a CXCR3 antagonist (EMD Millipore), or 500pg/ml of the CD26 
inhibitor (Santa Cruz Biotechnology) for 24 hours. These cells were then stimulated with 
viral antigens or anti-CD3 (Hit3a clone, BD Pharmigen) and used in the ELISpot, flow 
cytometry, Luminex, and Ca2+ flux assays (figure 4.1). Average cell viability post 
treatment with IP-10 was 95.1±3.3% and 89.2±3.2% for the healthy HIV-negative and 
HIV-infected on ART samples, respectively (figure 4.2).  
iii. IFN-! ELISpot 
A standard IFN-! ELISpot (MABtech, Nacka, Sweden) assay as previously 
described was used262. Briefly, PBMCs were treated with or without rhIP-10 for 24 hours 
prior to this assay and then plated in triplicate at 2x105 cells per well.  PBMCs from 
healthy HIV-negative subjects were also treated for 24 hours with a CXCR3 antagonist 
(500pg/ml; EMD Millipore). PBMCs from HIV-1 infected subjects on ART were also 
treated for 24 hours with a CD26 inhibitor (500pg/ml; Santa Cruz Biotechnology). Cells 
were then either stimulated with media alone, CD8+ specific CEF peptides (0.03µg/ml: 
CMV, EBV, Flu peptides) or influenza proteins (Protein Sciences Corp.: 
A/Brisbane/59/07, 10µg/ml; A/Brisbane/10/07, 10µg/ml; B/Brisbane/60/08, 10µg/ml). 
PBMCs from HIV-1 infected subjects on ART were also stimulated with HIV-1 consensus 
sequence subtype B gag peptides (2µg/ml), in the presence or absence of 500pg/ml IP-
10 or ±1µg/ml of the anti-IP-10 neutralizing monoclonal antibody (R & D Systems). 
PMA/Ionomycin (0.02µg/mL and 2µg/ml respectively) was done in triplicate as positive 
controls. BCIP/NBT was used to visualize spots. The spots were counted on an 
ImmunoSpot plate reader. For the healthy HIV-1 negative subjects, IFN-! production in 
the absence of IP-10 was compared to that of each dose treatment with IP-10 using a 
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Friedman Test followed by Dunn’s multiple comparison test. For the HIV-1 infected 
subjects on ART a Wilcoxon matched-pairs signed rank test was used to examine the 
effect of IP-10 or effect of blocking IP-10 on IFN-! production. To examine the effect of 
the CXCR3 antagonist or the CD26 inhibitor on IFN-! production a paired t-test was 
used. 
iv. Luminex 
a. A Luminex cytokine/chemokine assay (Millipore) was used to examine serum 
from 15 HIV-1 infected subjects on ART, 13 untreated HIV-1 infected subjects, and 10 
healthy HIV-negative controls. The assay examined the following serum 
cytokine/chemokine levels: IL-12p40, IL-12p70, IFN-!, TNF-", IL-10, IL-4, IL-5, IL-6, IL-
13, IL-2, IL-7, IL-15, G-CSF, GM-CSF, VEFG, TGF-", EGF, IP-10, MIP-1", MIP-1#, IL-8, 
MCP-1, Fractalkine, Eotaxin, IL-17A, IL-1ra, IL-1", IL-1#, sCD40L. Cytokine/chemokine 
profiles were compared between the HIV-1 infected individuals on ART and the HIV-
negative controls using an unpaired t-test. A Kruskal-Wallis test followed by Dunn’s 
multiple comparison test was used to compare the levels of IP-10 between untreated 
HIV-1 positive subjects, HIV-1 infected subjects on ART, and healthy HIV-negative 
controls. 
b. Supernatants from stimulated HIV-1 infected lymphocytes on ART with and 
without IP-10 (500pg/ml) treatment were isolated.  A Luminex assay (Millipore) panel 
was used to assess cytokine secretion and the impact of IP-10 on CD3 (Hit3a clone, BD 
Pharmigen, 5µg/ml) and CD28/CD49d (1µg/ml) stimulated lymphocytes. The assay 
examined secretion of: EGF, Eotaxin, G-CSF, GM-CSF, IFN"2, IFN-!, IL-1", IL-1#, IL-
1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17A, 
MCP-1, MIP-1", MIP-1#, TNF-", TNF-#, and VEGF. Positive controls included in the 
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Luminex assay ensured that the assay was able to detect the cytokines/markers 
analyzed. Immunological molecule secretion in response to stimulation in media alone 
was compared to the PBMCs treated with 500pg/ml of IP-10 or treated with 1µg/ml of the 
anti-IP-10 NAb using a repeated-measures ANOVA followed by Bonferroni’s multiple 
comparison test.  
c. Cell lysates were isolated from HIV-negative PBMCs treated with or without 
IP-10 followed by stimulation with CEF peptides or influenza proteins. The assay 
(Millipore) examined the expression of the phosphorylation sites of the following 
phospho-proteins: ATF2 (Thr71), Erk (Thr185/Tyr187), HSP27 (Ser78), JNK 
(Thr183/Tyr185), MEK1 (Ser222), MSK1 (Ser212), STAT1 (Tyr707), c-Jun (Ser73), p38 
(Thr180/Tyr182), p53 (Ser15). To examine the fold change in the mean fluorescence 
intensity (MFI) of phosphorylated proteins, the media alone condition was divided from 
that of the IP-10 treated condition. Following this, a Wilcoxon matched-pairs signed rank 
test was used to investigate whether IP-10 treatment led to a significant change in 
expression of the phosphorylated proteins of interest. 
d. IP-10 3-Plex: Plasma samples from healthy HIV-negative subjects, HIV-1 
infected subjects on ART, and untreated HIV-1 infected subjects were sent to Myriad-
RBM. Plasma samples were then run on their IP-10 3-plex assay to asses the levels of 
Total, Long, and Short form of IP-10. IP-10 short form levels relative to Total IP-10 levels 
were then compared using a One-way ANOVA followed by Bonferroni’s multiple 
comparison test. 
v. Flow Cytometry 
 a. IFN-! expression:  A multi-parameter flow cytometry panel was used to 
examine the effect of IP-10 treatment (500pg/ml) had on IFN-! expression in total 
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PBMCs and isolated CD4+ and CD8+ T-cells. The antibodies are as follows: BD 
Biosciences: CD14, 16 (PacBlue), CD4 (PerCp-Cy5.5), IFN-! (FITC), CXCR3 (APC); 
Biolegend: CD3 (APC-Cy7), CD8 (APC); Invitrogen: CD19 (PacBlue), LIVE/DEAD Violet. 
To determine the background expression of IFN-!, a no stimulation control was used. 
Total PBMCs, CD4+ T-cells alone, and CD8+ T-cells alone were stimulated with anti-
CD3 (Hit3a clone) and co-stimulatory antibodies, CD28 and CD49d, as previously 
discussed by Betts et al.260. To examine the change in IFN-! expression, the media 
alone condition was compared to that of the IP-10 treated condition. Following this a 
paired t-test was used to examine whether IP-10 treatment led to a significant change in 
IFN-! expression. 
b. CD8+ Cytotoxic Panel:  A multi-parameter flow cytometry panel was created to 
examine the effect of blocking IP-10 using a neutralizing anti-IP-10 antibody (R & D 
Systems) on the ability of CD8+ T-cells to degranulate and produce perforin and 
granzyme B. PBMCs from HIV-1 infected subjects on ART received ±1µg/ml anti-IP-10 
mAb and ± consensus sequence subtype B gag peptides (2µg/ml) for 24 hours. These 
PBMCs were then used for the multi-parameter flow cytometry assay as described by 
Betts et al.260. The antibodies are as follows: BD Biosciences: CD14, 16 (PacBlue), 
CD107a (PE-Cy7); Biolegend: CD3 (BV510), CD8 (BV570); Invitrogen: CD19 (PacBlue), 
Viability Dye (Violet), Granzyme B (PE-Texas Red); Ebiosciences: CD4 (PE-Cy5.5); 
Abcam: Perforin (PE).  A Friedman Test was used to examine the effect of blocking IP-
10 on CD8+ triple positive degranulation and perforin/granzyme B production.   
c. Ca2+ Flux assay: 1) PBMCs or CD4+ or CD8+ T-cells alone from HIV-negative 
individuals were cultured as discussed above in the presence (500 or 100,000pg/ml) or 
absence of rhIP-10 (Biolegend) for 24 hours.  
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2) Or PBMCs from healthy HIV-negative subjects were treated for 24 hours with 
a CXCR3 antagonist (500pg/ml; EMD Millipore).  
3) Or PBMCs from HIV-1 infected subjects on ART were treated for 24 hours with 
a CD26 inhibitor (500pg/ml; Santa Cruz Biotechnology). 
Following this, these PBMCs, CD4+ or CD8+ T-cells were washed and placed in 
a calcium containing solution (140mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1mM MgCl2, 
10mM HEPES pH=7.4, 10mM D-glucose) and were loaded with Fura-2, AM (3uM, 
Invitrogen) for 30-45 minutes at room temperature. Fifteen minutes prior to analysis on 
the LSRB, mouse anti-human CD3 (50ng/ml, OKT3, eBioscience) was added to allow for 
stimulation via CD3 crosslinking using a purified goat anti-mouse IgG polyclonal 
antibody (Biolegend) against the anti-CD3 antibody. At the time of analysis on the LSRB, 
control groups containing cells only, cells in calcium free solution, and cells + fura-2, AM 
were run to establish background and baseline fluorescence of the fura-2, AM. Change 
in fluorescence intensity from media alone was examined using a Friedman Test to 
determine whether treatment with IP-10 led to a change in the calcium response in 
PBMCs, CD4+ and CD8+ T-cells alone. To examine the change in mean fluorescence 
intensity from media alone compared to effect of the CXCR3 antagonist or CD26 
inhibitor a paired t-test was used. 
d. T-cell proliferation: frozen PBMCs from HIV-1 infected subjects on ART were 
treated with media alone, or 1µg/ml of anti-IP-10 NAb for 24 hours. Following this, cells 
were incubated with CFSE (2.5µM) for 5 min at room temperature. Cells were washed 
and incubated with media alone, CEF peptides (0.03µg/ml), influenza proteins (Protein 
Sciences Corp.: A/Brisbane/59/07, 10µg/ml; A/Brisbane/10/07, 10µg/ml; 
B/Brisbane/60/08, 10µg/ml), gag peptides (2µg/ml), or Concanavalin A (ConA; positive 
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control) for 5 days at 37°C in 96-well plates. Cultures with medium alone were used to 
determine background proliferative responses. PBMCs were stained with the following 
mAbs: BD Biosciences: CD3 (APC-Cy7), CD4 (APC), and CD8 (PE-Cy7). Stained and 
fixed cells were acquired on the LSRII and analyzed using FlowJo software. The mean 
fluorescence intensity of CFSE was used to determine T-cell proliferative responses. A 
Wilcoxon matched-pairs signed rank test was used to examine the percentage of CFSE 
dim cells in media alone and 1µg/ml anti-IP10 within each of the antigen stimulation 
conditions. 
e. Multifunctional T-cell Panel: A multi-parameter flow cytometry panel was used 
to examine what effect IP-10 (500pg/ml) or anti-IP-10 (1µg/ml) treatment had on IL-2, 
MIP-1#, TNF-", and PD-1 expression in total PBMCs from HIV-1 infected subjects on 
ART. The antibodies are as follows: BD Biosciences: CD14, 16 (PacBlue), CD4 (PerCp-
Cy5.5), MIP-1# (FITC), CD3 (APC-Cy7), IL-2 (PE-Cy7); Biolegend: CD8 (BV650), PD-1 
(BV711), TNF-" (APC); Invitrogen: CD19 (PacBlue), LIVE/DEAD Violet. To determine 
background expression, a no stimulation control was used. Total PBMCs, were 
stimulated with anti-CD3 (Hit3a clone, BD Pharmigen, 5µg/ml) and co-stimulatory 
antibodies, CD28 and CD49d (1µg/ml), as previously discussed by Betts et al.258260. To 
examine the change in IL-2, MIP-1#, TNF-", and PD-1 expression, the media alone 
condition was compared to that of the IP-10 (500pg/ml) or anti-IP-10 (1µg/ml) treated 
conditions. A Friedman test followed by Dunn’s multiple comparison test was used to 
examine whether IP-10 or anti-IP-10 treatment led to a significant change in IL-2, MIP-
1#, TNF-", and PD-1 expression. 
f. MHC down-regulation: frozen PBMCs from healthy HIV-negative controls were 
treated with media alone or 500pg/ml of IP-10 for 24 hours. Following this PBMCs were 
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stained with the following mAbs: BD Biosciences: CD3 (APC-Cy7), CD4 (PerCp-Cy5.5); 
Biolegend: CD33 (BV711), CD8 (BV650), CD68 (APC), HLA-DR (PE); Sigma-Aldrich: 
HLA Class-I (FITC); Invitrogen: Viability Dye (Violet). Media alone was then compared to 
IP-10 treated PBMCs using a Wilcoxon matched-pairs signed rank test. 
g. CD26 Surface Expression: A multi-parameter flow cytometry panel was 
created to examine the effect of IP-10 treatment on CD26 (DPPIV) surface expression 
on T-cells. Frozen PBMCs from healthy HIV-negative controls were treated with media 
alone or IP-10 (500 or 100,000pg/ml) for 24 hours. Following this PBMCs were stained 
with the following antibodies: BD Biosciences: CD3 (APC-Cy7), CD8 (APC), CD4 
(PerCP-Cy5.5), CD26/DPPIV (FITC), CD14, 16 (PacBlue); Invitrogen: CD19 (Pacblue), 
Live/Dead Violet. Media alone was then compared to IP-10 treated (500 or 
100,000pg/ml) PBMCs using a Friedman Test.  
vi. ELISA 
We used a standard ELISA kit (Millipore) to quantify soluble CD26 levels from 
sera of 15 HIV-1 infected subjects on ART and 10 healthy HIV-negative individuals. 
Preparation of reagents and protocol was followed according to manual instructions. 
Color intensity (absorbance) was then measured at 450nm on an ELISA microwell 
reader. The absorbance values of the HIV-1 infected subjects on ART were compared to 
those of the HIV-negative subjects using an unpaired t-test.   
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